{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "d28da347",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/markdown": [
       "**Note:** `torch` or `torch_geometric` not detected. You can still run the NetworkX-based EDA. If you want PyG for modeling, install compatible torch + torch_geometric (see PyG docs)."
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import os, sys, re, math, random, gc\n",
    "from collections import Counter, defaultdict\n",
    "import pandas as pd\n",
    "import numpy as np\n",
    "import matplotlib.pyplot as plt\n",
    "import seaborn as sns\n",
    "from IPython.display import display, Markdown\n",
    "\n",
    "pd.set_option('display.max_colwidth', 400)\n",
    "pd.set_option('display.max_columns', 80)\n",
    "pd.set_option('display.width', 160)\n",
    "\n",
    "def try_import(name, import_name=None):\n",
    "    try:\n",
    "        if import_name:\n",
    "            module = __import__(import_name, fromlist=[name])\n",
    "        else:\n",
    "            module = __import__(name)\n",
    "        return module, None\n",
    "    except Exception as e:\n",
    "        return None, e\n",
    "\n",
    "torch, err_torch = try_import(\"torch\", \"torch\")\n",
    "pyg, err_pyg = try_import(\"torch_geometric\", \"torch_geometric\")\n",
    "if torch is None or pyg is None:\n",
    "    display(Markdown(\"**Note:** `torch` or `torch_geometric` not detected. You can still run the NetworkX-based EDA. If you want PyG for modeling, install compatible torch + torch_geometric (see PyG docs).\"))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "id": "5556de19",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/markdown": [
       "### Preview (first 500 rows)"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>type</th>\n",
       "      <th>created</th>\n",
       "      <th>updated</th>\n",
       "      <th>drugbank-id</th>\n",
       "      <th>name</th>\n",
       "      <th>description</th>\n",
       "      <th>cas-number</th>\n",
       "      <th>unii</th>\n",
       "      <th>state</th>\n",
       "      <th>groups</th>\n",
       "      <th>synthesis-reference</th>\n",
       "      <th>indication</th>\n",
       "      <th>pharmacodynamics</th>\n",
       "      <th>mechanism-of-action</th>\n",
       "      <th>toxicity</th>\n",
       "      <th>metabolism</th>\n",
       "      <th>absorption</th>\n",
       "      <th>half-life</th>\n",
       "      <th>protein-binding</th>\n",
       "      <th>route-of-elimination</th>\n",
       "      <th>volume-of-distribution</th>\n",
       "      <th>clearance</th>\n",
       "      <th>atc-codes</th>\n",
       "      <th>ahfs-codes</th>\n",
       "      <th>pdb-entries</th>\n",
       "      <th>food-interactions</th>\n",
       "      <th>drug-interactions</th>\n",
       "      <th>sequences</th>\n",
       "      <th>enzymes</th>\n",
       "      <th>pathways</th>\n",
       "      <th>reactions</th>\n",
       "      <th>snp-effects</th>\n",
       "      <th>snp-adverse-drug-reactions</th>\n",
       "      <th>targets</th>\n",
       "      <th>carriers</th>\n",
       "      <th>transporters</th>\n",
       "      <th>fda-label</th>\n",
       "      <th>msds</th>\n",
       "      <th>average-mass</th>\n",
       "      <th>monoisotopic-mass</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>biotech</td>\n",
       "      <td>2005-06-13</td>\n",
       "      <td>2023-01-03</td>\n",
       "      <td>DB00001</td>\n",
       "      <td>Lepirudin</td>\n",
       "      <td>Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.[L41539,L41569] Natural hirudin is an endogenous anticoagulant found in _Hirudo medicinalis_ leeches.[L41539] Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence of sulfate on the tyrosine residue at position 63 and the substitutio...</td>\n",
       "      <td>138068-37-8</td>\n",
       "      <td>Y43GF64R34</td>\n",
       "      <td>solid</td>\n",
       "      <td>approved withdrawn</td>\n",
       "      <td>Recombinant hirudin expressed by using yeast secretary (China Patent No. CN1371994A, 2001). China National Intellectual Property Administration. https://patents.google.com/patent/CN1371994A/en</td>\n",
       "      <td>Lepirudin is indicated for anticoagulation in adult patients with acute coronary syndromes (ACS) such as unstable angina and acute myocardial infarction without ST elevation. In patients with ACS, lepirudin is intended for use with [aspirin].[L41539] Lepirudin is also indicated for anticoagulation in patients with heparin-induced thrombocytopenia (HIT) and associated thromboembolic disease in ...</td>\n",
       "      <td>Lepirudin is a recombinant hirudin that acts as a highly specific thrombin inhibitor. Its activity is measured by anti-thrombin units (ATUs) that correspond to the amount of lepirudin required to neutralize a unit of the World Health Organization α-thrombin (89/588) standard. The activity of lepirudin is 16,000 ATU/mg.[L41539,L41569] A single molecule of lepirudin binds to a molecule of thromb...</td>\n",
       "      <td>Lepirudin is a direct thrombin inhibitor used as an anticoagulant in patients for whom heparin is contraindicated.[L41539,A3] Thrombin is a serine protease that participates in the blood-clotting cascade, and it is formed by the cleavage of pro-thrombin. Active thrombin cleaves fibrinogen and generates fibrin monomers that polymerize to form fibrin clots.[A246624]\\n\\nLepirudin binds to the cat...</td>\n",
       "      <td>The acute toxicity of intravenous lepirudin was evaluated in mice (0.1-1000 mg/kg), rats (1-1000 mg/kg), and monkeys (1-100 mg/kg), and toxicity was not detected at the doses investigated.[L41539] The acute toxicity of lepirudin administered subcutaneously was also evaluated in mice (1-1250 mg/kg) and rats (1-500 mg/kg), and no toxicity was detected.[L41539] One rat (100 mg/kg) died of rapid b...</td>\n",
       "      <td>As a polypeptide, lepirudin is expected to be metabolized by the sequential cleavage of amino acids by kidney exoproteases, which have carboxypeptidase and dipeptidase-like activity.[L41539,L41544] The C-terminal cleavage of lepirudin aminoacids (aminoacids 1 to 65) produces four metabolites with anti-thrombotic activity: M1 (aminoacids 1 to 64), M2 (aminoacids 1 to 63), M3 (aminoacids 1 to 62...</td>\n",
       "      <td>Lepirudin administered as a single intravenous bolus injection of 0.4 mg/kg in 9 healthy volunteers (male and female) resulted in a C&lt;sub&gt;max&lt;/sub&gt; of 2924 ng/mL, a t&lt;sub&gt;max&lt;/sub&gt; of 0.17 h and an AUC&lt;sub&gt;0-∞&lt;/sub&gt; of 2500 ng•h/mL.[L41539] When 0.1, 0.15 and 0.2 mg/kg of lepirudin was administered as a single intravenous infusion over 6 hours in healthy male volunteers, lepirudin had a corres...</td>\n",
       "      <td>Lepirudin has an initial half-life of approximately 10 minutes, and in young healthy volunteers, it has a terminal half-time of 1.3 hours.[L41539] Lepirudin has a first-order elimination kinetic; plasma concentration increases proportionally as the lepirudin intravenous dose is increased. Elimination half-life values of up to 2 days were detected in patients with marked renal insufficiency (cr...</td>\n",
       "      <td>In human plasma, the protein binding of lepirudin was approximately 3%.[L41539]</td>\n",
       "      <td>Lepirudin is mostly excreted through urine (48.3%). About 35% of lepirudin is excreted unchanged, while metabolites are found in a smaller proportion (2.5% of M1, 5.4% of M2, 3.9% of M3 and 1.6% of M4).[L41544]</td>\n",
       "      <td>The volume of distribution of lepirudin at steady state was 12.2 L in healthy young subjects (n=18, 18-60 years), 18.7 L in healthy elderly subjects (n=10, 65-80 years), 18.0 L in renally impaired subjects (n=16, creatinine clearance &lt; 80 mL/min, and 32.1 L in heparin-induced thrombocytopenia patients (n=73).[L41539] The distribution of lepirudin is mainly restricted to extracellular fluids.[L...</td>\n",
       "      <td>The clearance of lepirudin is proportional to the glomerular filtration rate. On average, lepirudin clearance was 164 mL/min in healthy young subjects (n=18, 18-60 years) and 25% lower in women than in men. In healthy elderly subjects (n=10, 65-80 years), clearance was 139 mL/min, about 20% lower than in younger patients.[L41539] This is possibly due to the lower creatinine clearance in elderl...</td>\n",
       "      <td>BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS Direct thrombin inhibitors</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include chamomile, garlic, ginger, ginkgo and ginseng.</td>\n",
       "      <td>DB13821 DB00328 DB08953 DB00682 DB00928 DB09124 DB13400 DB09381 DB00656 DB09052 DB06679 DB06737 DB03374 DB08814 DB12289 DB06251 DB09217 DB11133 DB00970 DB01066 DB13875 DB13876 DB00034 DB00814 DB00562 DB00036 DB09253 DB01247 DB14006 DB01942 DB00642 DB13510 DB13286 DB00495 DB00232 DB13432 DB13199 DB00105 DB06228 DB13947 DB00305 DB00605 DB00957 DB06715 DB06772 DB01327 DB01543 DB08984 DB01229 DB12...</td>\n",
       "      <td>&gt;DB00001 sequence\\nLTYTDCTESGQNLCLCEGSNVCGQGNKCILGSDGEKNQCVTGEGTPKPQSHNDGDFEEIP\\nEEYLQ</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>P00488 P00748 P38435 Q9BQB6 P00734 P08709 P03952 P00451 P13726 P00742 P03951 P00740 P00747 P02671 P05160 P02679 P02452 P02675 P00750 P12259</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>BE0000048</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>biotech</td>\n",
       "      <td>2005-06-13</td>\n",
       "      <td>2023-01-03</td>\n",
       "      <td>DB00002</td>\n",
       "      <td>Cetuximab</td>\n",
       "      <td>Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF).[A227973] EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible for regulating epithelial tissue development and ho...</td>\n",
       "      <td>205923-56-4</td>\n",
       "      <td>PQX0D8J21J</td>\n",
       "      <td>liquid</td>\n",
       "      <td>approved</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Cetuximab indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy. It is indicated for treating a recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil. It is indicated for recurrent or metastatic squamous cell...</td>\n",
       "      <td>Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.[L31418] Cetuximab works by inhibiting the growth and survival of EGFR-positive tumours.[A...</td>\n",
       "      <td>The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein and a type I receptor tyrosine kinase expressed on both normal and malignant cells. It has been investigated as a therapeutic target for anticancer treatment, as it is often upregulated in cancer types, including head and neck, colon, and rectal cancers.[L30448] When activated by its ligand, EGFR undergoes a conformati...</td>\n",
       "      <td>The intravenous LD&lt;sub&gt;50&lt;/sub&gt; is &gt; 300 mg/kg in mice and &gt; 200 mg/kg in rats.[L31408] There is limited information on the overdose from cetuximab.\\n\\nIn clinical trials, cetuximab was associated with serious and fatal infusion reactions, cardiopulmonary arrest or sudden death, and serious dermatologic toxicities. Pulmonary toxicities, such as interstitial lung disease, interstitial pneumonit...</td>\n",
       "      <td>Like other monoclonal antibodies, cetuximab is expected to undergo lysosomal degradation by the reticuloendothelial system and protein catabolism by a target‐mediated disposition pathway.[A40006]</td>\n",
       "      <td>After administration of a 400 mg/m&lt;sup&gt;2&lt;/sup&gt; initial dose followed by a 250 mg/m&lt;sup&gt;2&lt;/sup&gt; weekly dose, the steady-state levels of cetuximab was reached by the third weekly infusion with mean peak and trough concentrations across studies ranging from 168 µg/mL to 235 µg/mL and 41 µg/mL to 85 µg/mL, respectively.[L30448] T&lt;sub&gt;max&lt;/sub&gt; is about 3 hours.[A227963]</td>\n",
       "      <td>After administration of a 400 mg/m&lt;sup&gt;2&lt;/sup&gt; initial dose followed by a 250 mg/m&lt;sup&gt;2&lt;/sup&gt; weekly dose, the mean half-life for cetuximab was approximately 112 hours, with a range of 63 to 230 hours.[L30448]</td>\n",
       "      <td>There is no information available.</td>\n",
       "      <td>There is limited information available.</td>\n",
       "      <td>The volume of the distribution is about 2-3 L/m&lt;sup&gt;2&lt;/sup&gt; and is independent of dose.[L30448]</td>\n",
       "      <td>In patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck, the estimated clearance rate was 0.103 L/h.[A228003] At doses ranging from 200 to 400 mg/m&lt;sup&gt;2&lt;/sup&gt;, complete saturation of systemic clearance was observed. In a population pharmacokinetic study,  female patients had a 25% lower intrinsic cetuximab clearance than male patients, although there was no e...</td>\n",
       "      <td>ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ANTINEOPLASTIC AGENTS EGFR (Epidermal Growth Factor Receptor) inhibitors</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB13259 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB00814 DB11604 DB12344 DB13886 DB05232 DB14811 DB11884 DB11685 DB11746 DB15118 DB01086 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB01075 DB00108 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06...</td>\n",
       "      <td>&gt;Cetuximab light chain\\nDILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPS\\nRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPP\\nSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT\\nLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC &gt;Cetuximab heavy chain\\nQVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYN\\nTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAA\\nSTK...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00002.pdf?1265922813</td>\n",
       "      <td>//s3-us-west-2.amazonaws.com/drugbank/msds/DB00002.pdf?1458412933</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>P00533</td>\n",
       "      <td>NaN</td>\n",
       "      <td>P08637 P12318</td>\n",
       "      <td>NaN</td>\n",
       "      <td>BE0002096 BE0000767 BE0000710 BE0002097 BE0002094 BE0002098 BE0000901 BE0002095</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "      type     created     updated drugbank-id       name  \\\n",
       "0  biotech  2005-06-13  2023-01-03     DB00001  Lepirudin   \n",
       "1      NaN         NaN         NaN         NaN        NaN   \n",
       "2      NaN         NaN         NaN         NaN        NaN   \n",
       "3  biotech  2005-06-13  2023-01-03     DB00002  Cetuximab   \n",
       "4      NaN         NaN         NaN         NaN        NaN   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                       description  \\\n",
       "0  Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.[L41539,L41569] Natural hirudin is an endogenous anticoagulant found in _Hirudo medicinalis_ leeches.[L41539] Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence of sulfate on the tyrosine residue at position 63 and the substitutio...   \n",
       "1                                                                                                                                                                                                                                                                                                                                                                                                              NaN   \n",
       "2                                                                                                                                                                                                                                                                                                                                                                                                              NaN   \n",
       "3  Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF).[A227973] EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible for regulating epithelial tissue development and ho...   \n",
       "4                                                                                                                                                                                                                                                                                                                                                                                                              NaN   \n",
       "\n",
       "    cas-number        unii   state              groups  \\\n",
       "0  138068-37-8  Y43GF64R34   solid  approved withdrawn   \n",
       "1          NaN         NaN     NaN                 NaN   \n",
       "2          NaN         NaN     NaN                 NaN   \n",
       "3  205923-56-4  PQX0D8J21J  liquid            approved   \n",
       "4          NaN         NaN     NaN                 NaN   \n",
       "\n",
       "                                                                                                                                                                                synthesis-reference  \\\n",
       "0  Recombinant hirudin expressed by using yeast secretary (China Patent No. CN1371994A, 2001). China National Intellectual Property Administration. https://patents.google.com/patent/CN1371994A/en   \n",
       "1                                                                                                                                                                                               NaN   \n",
       "2                                                                                                                                                                                               NaN   \n",
       "3                                                                                                                                                                                               NaN   \n",
       "4                                                                                                                                                                                               NaN   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                        indication  \\\n",
       "0  Lepirudin is indicated for anticoagulation in adult patients with acute coronary syndromes (ACS) such as unstable angina and acute myocardial infarction without ST elevation. In patients with ACS, lepirudin is intended for use with [aspirin].[L41539] Lepirudin is also indicated for anticoagulation in patients with heparin-induced thrombocytopenia (HIT) and associated thromboembolic disease in ...   \n",
       "1                                                                                                                                                                                                                                                                                                                                                                                                              NaN   \n",
       "2                                                                                                                                                                                                                                                                                                                                                                                                              NaN   \n",
       "3  Cetuximab indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy. It is indicated for treating a recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil. It is indicated for recurrent or metastatic squamous cell...   \n",
       "4                                                                                                                                                                                                                                                                                                                                                                                                              NaN   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                  pharmacodynamics  \\\n",
       "0  Lepirudin is a recombinant hirudin that acts as a highly specific thrombin inhibitor. Its activity is measured by anti-thrombin units (ATUs) that correspond to the amount of lepirudin required to neutralize a unit of the World Health Organization α-thrombin (89/588) standard. The activity of lepirudin is 16,000 ATU/mg.[L41539,L41569] A single molecule of lepirudin binds to a molecule of thromb...   \n",
       "1                                                                                                                                                                                                                                                                                                                                                                                                              NaN   \n",
       "2                                                                                                                                                                                                                                                                                                                                                                                                              NaN   \n",
       "3  Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.[L31418] Cetuximab works by inhibiting the growth and survival of EGFR-positive tumours.[A...   \n",
       "4                                                                                                                                                                                                                                                                                                                                                                                                              NaN   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                               mechanism-of-action  \\\n",
       "0  Lepirudin is a direct thrombin inhibitor used as an anticoagulant in patients for whom heparin is contraindicated.[L41539,A3] Thrombin is a serine protease that participates in the blood-clotting cascade, and it is formed by the cleavage of pro-thrombin. Active thrombin cleaves fibrinogen and generates fibrin monomers that polymerize to form fibrin clots.[A246624]\\n\\nLepirudin binds to the cat...   \n",
       "1                                                                                                                                                                                                                                                                                                                                                                                                              NaN   \n",
       "2                                                                                                                                                                                                                                                                                                                                                                                                              NaN   \n",
       "3  The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein and a type I receptor tyrosine kinase expressed on both normal and malignant cells. It has been investigated as a therapeutic target for anticancer treatment, as it is often upregulated in cancer types, including head and neck, colon, and rectal cancers.[L30448] When activated by its ligand, EGFR undergoes a conformati...   \n",
       "4                                                                                                                                                                                                                                                                                                                                                                                                              NaN   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                          toxicity  \\\n",
       "0  The acute toxicity of intravenous lepirudin was evaluated in mice (0.1-1000 mg/kg), rats (1-1000 mg/kg), and monkeys (1-100 mg/kg), and toxicity was not detected at the doses investigated.[L41539] The acute toxicity of lepirudin administered subcutaneously was also evaluated in mice (1-1250 mg/kg) and rats (1-500 mg/kg), and no toxicity was detected.[L41539] One rat (100 mg/kg) died of rapid b...   \n",
       "1                                                                                                                                                                                                                                                                                                                                                                                                              NaN   \n",
       "2                                                                                                                                                                                                                                                                                                                                                                                                              NaN   \n",
       "3  The intravenous LD<sub>50</sub> is > 300 mg/kg in mice and > 200 mg/kg in rats.[L31408] There is limited information on the overdose from cetuximab.\\n\\nIn clinical trials, cetuximab was associated with serious and fatal infusion reactions, cardiopulmonary arrest or sudden death, and serious dermatologic toxicities. Pulmonary toxicities, such as interstitial lung disease, interstitial pneumonit...   \n",
       "4                                                                                                                                                                                                                                                                                                                                                                                                              NaN   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                        metabolism  \\\n",
       "0  As a polypeptide, lepirudin is expected to be metabolized by the sequential cleavage of amino acids by kidney exoproteases, which have carboxypeptidase and dipeptidase-like activity.[L41539,L41544] The C-terminal cleavage of lepirudin aminoacids (aminoacids 1 to 65) produces four metabolites with anti-thrombotic activity: M1 (aminoacids 1 to 64), M2 (aminoacids 1 to 63), M3 (aminoacids 1 to 62...   \n",
       "1                                                                                                                                                                                                                                                                                                                                                                                                              NaN   \n",
       "2                                                                                                                                                                                                                                                                                                                                                                                                              NaN   \n",
       "3                                                                                                                                                                                                              Like other monoclonal antibodies, cetuximab is expected to undergo lysosomal degradation by the reticuloendothelial system and protein catabolism by a target‐mediated disposition pathway.[A40006]   \n",
       "4                                                                                                                                                                                                                                                                                                                                                                                                              NaN   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                        absorption  \\\n",
       "0  Lepirudin administered as a single intravenous bolus injection of 0.4 mg/kg in 9 healthy volunteers (male and female) resulted in a C<sub>max</sub> of 2924 ng/mL, a t<sub>max</sub> of 0.17 h and an AUC<sub>0-∞</sub> of 2500 ng•h/mL.[L41539] When 0.1, 0.15 and 0.2 mg/kg of lepirudin was administered as a single intravenous infusion over 6 hours in healthy male volunteers, lepirudin had a corres...   \n",
       "1                                                                                                                                                                                                                                                                                                                                                                                                              NaN   \n",
       "2                                                                                                                                                                                                                                                                                                                                                                                                              NaN   \n",
       "3                                 After administration of a 400 mg/m<sup>2</sup> initial dose followed by a 250 mg/m<sup>2</sup> weekly dose, the steady-state levels of cetuximab was reached by the third weekly infusion with mean peak and trough concentrations across studies ranging from 168 µg/mL to 235 µg/mL and 41 µg/mL to 85 µg/mL, respectively.[L30448] T<sub>max</sub> is about 3 hours.[A227963]   \n",
       "4                                                                                                                                                                                                                                                                                                                                                                                                              NaN   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                         half-life  \\\n",
       "0  Lepirudin has an initial half-life of approximately 10 minutes, and in young healthy volunteers, it has a terminal half-time of 1.3 hours.[L41539] Lepirudin has a first-order elimination kinetic; plasma concentration increases proportionally as the lepirudin intravenous dose is increased. Elimination half-life values of up to 2 days were detected in patients with marked renal insufficiency (cr...   \n",
       "1                                                                                                                                                                                                                                                                                                                                                                                                              NaN   \n",
       "2                                                                                                                                                                                                                                                                                                                                                                                                              NaN   \n",
       "3                                                                                                                                                                                               After administration of a 400 mg/m<sup>2</sup> initial dose followed by a 250 mg/m<sup>2</sup> weekly dose, the mean half-life for cetuximab was approximately 112 hours, with a range of 63 to 230 hours.[L30448]   \n",
       "4                                                                                                                                                                                                                                                                                                                                                                                                              NaN   \n",
       "\n",
       "                                                                   protein-binding  \\\n",
       "0  In human plasma, the protein binding of lepirudin was approximately 3%.[L41539]   \n",
       "1                                                                              NaN   \n",
       "2                                                                              NaN   \n",
       "3                                               There is no information available.   \n",
       "4                                                                              NaN   \n",
       "\n",
       "                                                                                                                                                                                                 route-of-elimination  \\\n",
       "0  Lepirudin is mostly excreted through urine (48.3%). About 35% of lepirudin is excreted unchanged, while metabolites are found in a smaller proportion (2.5% of M1, 5.4% of M2, 3.9% of M3 and 1.6% of M4).[L41544]   \n",
       "1                                                                                                                                                                                                                 NaN   \n",
       "2                                                                                                                                                                                                                 NaN   \n",
       "3                                                                                                                                                                             There is limited information available.   \n",
       "4                                                                                                                                                                                                                 NaN   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                            volume-of-distribution  \\\n",
       "0  The volume of distribution of lepirudin at steady state was 12.2 L in healthy young subjects (n=18, 18-60 years), 18.7 L in healthy elderly subjects (n=10, 65-80 years), 18.0 L in renally impaired subjects (n=16, creatinine clearance < 80 mL/min, and 32.1 L in heparin-induced thrombocytopenia patients (n=73).[L41539] The distribution of lepirudin is mainly restricted to extracellular fluids.[L...   \n",
       "1                                                                                                                                                                                                                                                                                                                                                                                                              NaN   \n",
       "2                                                                                                                                                                                                                                                                                                                                                                                                              NaN   \n",
       "3                                                                                                                                                                                                                                                                                                                  The volume of the distribution is about 2-3 L/m<sup>2</sup> and is independent of dose.[L30448]   \n",
       "4                                                                                                                                                                                                                                                                                                                                                                                                              NaN   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                         clearance  \\\n",
       "0  The clearance of lepirudin is proportional to the glomerular filtration rate. On average, lepirudin clearance was 164 mL/min in healthy young subjects (n=18, 18-60 years) and 25% lower in women than in men. In healthy elderly subjects (n=10, 65-80 years), clearance was 139 mL/min, about 20% lower than in younger patients.[L41539] This is possibly due to the lower creatinine clearance in elderl...   \n",
       "1                                                                                                                                                                                                                                                                                                                                                                                                              NaN   \n",
       "2                                                                                                                                                                                                                                                                                                                                                                                                              NaN   \n",
       "3  In patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck, the estimated clearance rate was 0.103 L/h.[A228003] At doses ranging from 200 to 400 mg/m<sup>2</sup>, complete saturation of systemic clearance was observed. In a population pharmacokinetic study,  female patients had a 25% lower intrinsic cetuximab clearance than male patients, although there was no e...   \n",
       "4                                                                                                                                                                                                                                                                                                                                                                                                              NaN   \n",
       "\n",
       "                                                                                                                                                                atc-codes  \\\n",
       "0                                                                                         BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS Direct thrombin inhibitors   \n",
       "1                                                                                                                                                                     NaN   \n",
       "2                                                                                                                                                                     NaN   \n",
       "3  ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ANTINEOPLASTIC AGENTS EGFR (Epidermal Growth Factor Receptor) inhibitors   \n",
       "4                                                                                                                                                                     NaN   \n",
       "\n",
       "   ahfs-codes  pdb-entries  \\\n",
       "0         NaN          NaN   \n",
       "1         NaN          NaN   \n",
       "2         NaN          NaN   \n",
       "3         NaN          NaN   \n",
       "4         NaN          NaN   \n",
       "\n",
       "                                                                                                                       food-interactions  \\\n",
       "0  Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include chamomile, garlic, ginger, ginkgo and ginseng.   \n",
       "1                                                                                                                                    NaN   \n",
       "2                                                                                                                                    NaN   \n",
       "3                                                                                                                                    NaN   \n",
       "4                                                                                                                                    NaN   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                 drug-interactions  \\\n",
       "0  DB13821 DB00328 DB08953 DB00682 DB00928 DB09124 DB13400 DB09381 DB00656 DB09052 DB06679 DB06737 DB03374 DB08814 DB12289 DB06251 DB09217 DB11133 DB00970 DB01066 DB13875 DB13876 DB00034 DB00814 DB00562 DB00036 DB09253 DB01247 DB14006 DB01942 DB00642 DB13510 DB13286 DB00495 DB00232 DB13432 DB13199 DB00105 DB06228 DB13947 DB00305 DB00605 DB00957 DB06715 DB06772 DB01327 DB01543 DB08984 DB01229 DB12...   \n",
       "1                                                                                                                                                                                                                                                                                                                                                                                                              NaN   \n",
       "2                                                                                                                                                                                                                                                                                                                                                                                                              NaN   \n",
       "3  DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB13259 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB00814 DB11604 DB12344 DB13886 DB05232 DB14811 DB11884 DB11685 DB11746 DB15118 DB01086 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB01075 DB00108 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06...   \n",
       "4                                                                                                                                                                                                                                                                                                                                                                                                              NaN   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                         sequences  \\\n",
       "0                                                                                                                                                                                                                                                                                                                           >DB00001 sequence\\nLTYTDCTESGQNLCLCEGSNVCGQGNKCILGSDGEKNQCVTGEGTPKPQSHNDGDFEEIP\\nEEYLQ   \n",
       "1                                                                                                                                                                                                                                                                                                                                                                                                              NaN   \n",
       "2                                                                                                                                                                                                                                                                                                                                                                                                              NaN   \n",
       "3  >Cetuximab light chain\\nDILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPS\\nRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPP\\nSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT\\nLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC >Cetuximab heavy chain\\nQVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYN\\nTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAA\\nSTK...   \n",
       "4                                                                                                                                                                                                                                                                                                                                                                                                              NaN   \n",
       "\n",
       "   enzymes                                                                                                                                     pathways  \\\n",
       "0      NaN                                                                                                                                          NaN   \n",
       "1      NaN                                                                                                                                          NaN   \n",
       "2      NaN  P00488 P00748 P38435 Q9BQB6 P00734 P08709 P03952 P00451 P13726 P00742 P03951 P00740 P00747 P02671 P05160 P02679 P02452 P02675 P00750 P12259   \n",
       "3      NaN                                                                                                                                          NaN   \n",
       "4      NaN                                                                                                                                       P00533   \n",
       "\n",
       "   reactions    snp-effects  snp-adverse-drug-reactions                                                                          targets  carriers  \\\n",
       "0        NaN            NaN                         NaN                                                                              NaN       NaN   \n",
       "1        NaN            NaN                         NaN                                                                              NaN       NaN   \n",
       "2        NaN            NaN                         NaN                                                                        BE0000048       NaN   \n",
       "3        NaN            NaN                         NaN                                                                              NaN       NaN   \n",
       "4        NaN  P08637 P12318                         NaN  BE0002096 BE0000767 BE0000710 BE0002097 BE0002094 BE0002098 BE0000901 BE0002095       NaN   \n",
       "\n",
       "   transporters                                                                fda-label                                                               msds  \\\n",
       "0           NaN                                                                      NaN                                                                NaN   \n",
       "1           NaN                                                                      NaN                                                                NaN   \n",
       "2           NaN                                                                      NaN                                                                NaN   \n",
       "3           NaN  //s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00002.pdf?1265922813  //s3-us-west-2.amazonaws.com/drugbank/msds/DB00002.pdf?1458412933   \n",
       "4           NaN                                                                      NaN                                                                NaN   \n",
       "\n",
       "   average-mass  monoisotopic-mass  \n",
       "0           NaN                NaN  \n",
       "1           NaN                NaN  \n",
       "2           NaN                NaN  \n",
       "3           NaN                NaN  \n",
       "4           NaN                NaN  "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/markdown": [
       "Loaded dataframe shape: **(16762, 40)**"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/plain": [
       "['type',\n",
       " 'created',\n",
       " 'updated',\n",
       " 'drugbank-id',\n",
       " 'name',\n",
       " 'description',\n",
       " 'cas-number',\n",
       " 'unii',\n",
       " 'state',\n",
       " 'groups',\n",
       " 'synthesis-reference',\n",
       " 'indication',\n",
       " 'pharmacodynamics',\n",
       " 'mechanism-of-action',\n",
       " 'toxicity',\n",
       " 'metabolism',\n",
       " 'absorption',\n",
       " 'half-life',\n",
       " 'protein-binding',\n",
       " 'route-of-elimination',\n",
       " 'volume-of-distribution',\n",
       " 'clearance',\n",
       " 'atc-codes',\n",
       " 'ahfs-codes',\n",
       " 'pdb-entries',\n",
       " 'food-interactions',\n",
       " 'drug-interactions',\n",
       " 'sequences',\n",
       " 'enzymes',\n",
       " 'pathways',\n",
       " 'reactions',\n",
       " 'snp-effects',\n",
       " 'snp-adverse-drug-reactions',\n",
       " 'targets',\n",
       " 'carriers',\n",
       " 'transporters',\n",
       " 'fda-label',\n",
       " 'msds',\n",
       " 'average-mass',\n",
       " 'monoisotopic-mass']"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Cell 2: set path and load CSV (adjust csv_path to match your environment)\n",
    "csv_path = \"../DrugBank_data/drugbank.csv\"   # <-- update this path if your file is elsewhere\n",
    "\n",
    "if not os.path.exists(csv_path):\n",
    "    display(Markdown(f\"**CSV not found at `{csv_path}`.** Please update `csv_path` to the correct location and re-run this cell.\"))\n",
    "else:\n",
    "    # load a small head first\n",
    "    display(Markdown(\"### Preview (first 500 rows)\"))\n",
    "    display(pd.read_csv(csv_path, nrows=5).head())\n",
    "\n",
    "    # now load everything as strings (safer for IDs)\n",
    "    df = pd.read_csv(csv_path, dtype=str, low_memory=False)\n",
    "    display(Markdown(f\"Loaded dataframe shape: **{df.shape}**\"))\n",
    "    display(df.columns.tolist())\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "41eac674",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/markdown": [
       "### Missingness % and unique counts"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>column</th>\n",
       "      <th>missing_pct</th>\n",
       "      <th>n_unique</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>drugbank-id</td>\n",
       "      <td>3.555662</td>\n",
       "      <td>15235</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>name</td>\n",
       "      <td>3.555662</td>\n",
       "      <td>15235</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>created</td>\n",
       "      <td>9.109891</td>\n",
       "      <td>760</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>type</td>\n",
       "      <td>9.109891</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>updated</td>\n",
       "      <td>9.109891</td>\n",
       "      <td>274</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>groups</td>\n",
       "      <td>9.109891</td>\n",
       "      <td>50</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>description</td>\n",
       "      <td>22.867200</td>\n",
       "      <td>8791</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>average-mass</td>\n",
       "      <td>30.879370</td>\n",
       "      <td>9972</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>39</th>\n",
       "      <td>monoisotopic-mass</td>\n",
       "      <td>30.879370</td>\n",
       "      <td>10030</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>unii</td>\n",
       "      <td>34.769121</td>\n",
       "      <td>10934</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>cas-number</td>\n",
       "      <td>43.007994</td>\n",
       "      <td>9527</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>state</td>\n",
       "      <td>45.286959</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>targets</td>\n",
       "      <td>53.066460</td>\n",
       "      <td>3895</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>pdb-entries</td>\n",
       "      <td>64.562701</td>\n",
       "      <td>5909</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>drug-interactions</td>\n",
       "      <td>73.284811</td>\n",
       "      <td>3618</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>indication</td>\n",
       "      <td>75.098437</td>\n",
       "      <td>3655</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>mechanism-of-action</td>\n",
       "      <td>76.655530</td>\n",
       "      <td>3853</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>atc-codes</td>\n",
       "      <td>79.698127</td>\n",
       "      <td>1171</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>pharmacodynamics</td>\n",
       "      <td>81.851808</td>\n",
       "      <td>3000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>toxicity</td>\n",
       "      <td>85.490992</td>\n",
       "      <td>2372</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>absorption</td>\n",
       "      <td>85.687865</td>\n",
       "      <td>2271</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>half-life</td>\n",
       "      <td>85.848944</td>\n",
       "      <td>2169</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>enzymes</td>\n",
       "      <td>86.272521</td>\n",
       "      <td>1072</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>metabolism</td>\n",
       "      <td>86.296385</td>\n",
       "      <td>2079</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>route-of-elimination</td>\n",
       "      <td>88.169669</td>\n",
       "      <td>1902</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>protein-binding</td>\n",
       "      <td>88.754325</td>\n",
       "      <td>1676</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>volume-of-distribution</td>\n",
       "      <td>89.971364</td>\n",
       "      <td>1606</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>synthesis-reference</td>\n",
       "      <td>90.430736</td>\n",
       "      <td>1574</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>clearance</td>\n",
       "      <td>90.687269</td>\n",
       "      <td>1487</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>msds</td>\n",
       "      <td>91.098914</td>\n",
       "      <td>1492</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>food-interactions</td>\n",
       "      <td>91.779024</td>\n",
       "      <td>950</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>fda-label</td>\n",
       "      <td>92.745496</td>\n",
       "      <td>1216</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>transporters</td>\n",
       "      <td>93.527025</td>\n",
       "      <td>510</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>carriers</td>\n",
       "      <td>96.098318</td>\n",
       "      <td>74</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>pathways</td>\n",
       "      <td>96.718769</td>\n",
       "      <td>148</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>reactions</td>\n",
       "      <td>97.351151</td>\n",
       "      <td>194</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>sequences</td>\n",
       "      <td>98.407111</td>\n",
       "      <td>263</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>snp-effects</td>\n",
       "      <td>99.522730</td>\n",
       "      <td>40</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>snp-adverse-drug-reactions</td>\n",
       "      <td>99.731536</td>\n",
       "      <td>36</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>ahfs-codes</td>\n",
       "      <td>100.000000</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                        column  missing_pct  n_unique\n",
       "3                  drugbank-id     3.555662     15235\n",
       "4                         name     3.555662     15235\n",
       "1                      created     9.109891       760\n",
       "0                         type     9.109891         2\n",
       "2                      updated     9.109891       274\n",
       "9                       groups     9.109891        50\n",
       "5                  description    22.867200      8791\n",
       "38                average-mass    30.879370      9972\n",
       "39           monoisotopic-mass    30.879370     10030\n",
       "7                         unii    34.769121     10934\n",
       "6                   cas-number    43.007994      9527\n",
       "8                        state    45.286959         3\n",
       "33                     targets    53.066460      3895\n",
       "24                 pdb-entries    64.562701      5909\n",
       "26           drug-interactions    73.284811      3618\n",
       "11                  indication    75.098437      3655\n",
       "13         mechanism-of-action    76.655530      3853\n",
       "22                   atc-codes    79.698127      1171\n",
       "12            pharmacodynamics    81.851808      3000\n",
       "14                    toxicity    85.490992      2372\n",
       "16                  absorption    85.687865      2271\n",
       "17                   half-life    85.848944      2169\n",
       "28                     enzymes    86.272521      1072\n",
       "15                  metabolism    86.296385      2079\n",
       "19        route-of-elimination    88.169669      1902\n",
       "18             protein-binding    88.754325      1676\n",
       "20      volume-of-distribution    89.971364      1606\n",
       "10         synthesis-reference    90.430736      1574\n",
       "21                   clearance    90.687269      1487\n",
       "37                        msds    91.098914      1492\n",
       "25           food-interactions    91.779024       950\n",
       "36                   fda-label    92.745496      1216\n",
       "35                transporters    93.527025       510\n",
       "34                    carriers    96.098318        74\n",
       "29                    pathways    96.718769       148\n",
       "30                   reactions    97.351151       194\n",
       "27                   sequences    98.407111       263\n",
       "31                 snp-effects    99.522730        40\n",
       "32  snp-adverse-drug-reactions    99.731536        36\n",
       "23                  ahfs-codes   100.000000         0"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/markdown": [
       "### Top 20 columns by coverage"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/plain": [
       "3     96.444338\n",
       "4     96.444338\n",
       "1     90.890109\n",
       "0     90.890109\n",
       "2     90.890109\n",
       "9     90.890109\n",
       "5     77.132800\n",
       "38    69.120630\n",
       "39    69.120630\n",
       "7     65.230879\n",
       "6     56.992006\n",
       "8     54.713041\n",
       "33    46.933540\n",
       "24    35.437299\n",
       "26    26.715189\n",
       "11    24.901563\n",
       "13    23.344470\n",
       "22    20.301873\n",
       "12    18.148192\n",
       "14    14.509008\n",
       "Name: missing_pct, dtype: float64"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Cell 3: missingness and unique counts\n",
    "if 'df' in globals():\n",
    "    missing_pct = df.isna().mean() * 100\n",
    "    info = pd.DataFrame({\n",
    "        \"column\": df.columns,\n",
    "        \"missing_pct\": missing_pct.values,\n",
    "        \"n_unique\": [df[c].nunique(dropna=True) for c in df.columns]\n",
    "    }).sort_values(\"missing_pct\")\n",
    "    display(Markdown(\"### Missingness % and unique counts\"))\n",
    "    display(info.head(80))\n",
    "    display(Markdown(\"### Top 20 columns by coverage\"))\n",
    "    display((100-info['missing_pct']).sort_values(ascending=False).head(20))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "d19d1d4a",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/markdown": [
       "Columns present from interest list: ['drugbank-id', 'name', 'targets', 'enzymes', 'transporters', 'carriers', 'pathways', 'reactions', 'snp-effects', 'snp-adverse-drug-reactions', 'drug-interactions', 'atc-codes', 'mechanism-of-action', 'description', 'half-life', 'protein-binding', 'average-mass', 'monoisotopic-mass', 'groups']"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/markdown": [
       "Sample parsed rows"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>drugbank-id</th>\n",
       "      <th>name</th>\n",
       "      <th>targets</th>\n",
       "      <th>enzymes</th>\n",
       "      <th>transporters</th>\n",
       "      <th>carriers</th>\n",
       "      <th>pathways</th>\n",
       "      <th>reactions</th>\n",
       "      <th>snp-effects</th>\n",
       "      <th>snp-adverse-drug-reactions</th>\n",
       "      <th>drug-interactions</th>\n",
       "      <th>atc-codes</th>\n",
       "      <th>mechanism-of-action</th>\n",
       "      <th>description</th>\n",
       "      <th>half-life</th>\n",
       "      <th>protein-binding</th>\n",
       "      <th>average-mass</th>\n",
       "      <th>monoisotopic-mass</th>\n",
       "      <th>groups</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>DB00001</td>\n",
       "      <td>Lepirudin</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[DB13821, DB00328, DB08953, DB00682, DB00928, DB09124, DB13400, DB09381, DB00656, DB09052, DB06679, DB06737, DB03374, DB08814, DB12289, DB06251, DB09217, DB11133, DB00970, DB01066, DB13875, DB13876, DB00034, DB00814, DB00562, DB00036, DB09253, DB01247, DB14006, DB01942, DB00642, DB13510, DB13286, DB00495, DB00232, DB13432, DB13199, DB00105, DB06228, DB13947, DB00305, DB00605, DB00957, DB06715,...</td>\n",
       "      <td>BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS Direct thrombin inhibitors</td>\n",
       "      <td>Lepirudin is a direct thrombin inhibitor used as an anticoagulant in patients for whom heparin is contraindicated.[L41539,A3] Thrombin is a serine protease that participates in the blood-clotting cascade, and it is formed by the cleavage of pro-thrombin. Active thrombin cleaves fibrinogen and generates fibrin monomers that polymerize to form fibrin clots.[A246624]\\n\\nLepirudin binds to the cat...</td>\n",
       "      <td>Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.[L41539,L41569] Natural hirudin is an endogenous anticoagulant found in _Hirudo medicinalis_ leeches.[L41539] Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence of sulfate on the tyrosine residue at position 63 and the substitutio...</td>\n",
       "      <td>Lepirudin has an initial half-life of approximately 10 minutes, and in young healthy volunteers, it has a terminal half-time of 1.3 hours.[L41539] Lepirudin has a first-order elimination kinetic; plasma concentration increases proportionally as the lepirudin intravenous dose is increased. Elimination half-life values of up to 2 days were detected in patients with marked renal insufficiency (cr...</td>\n",
       "      <td>In human plasma, the protein binding of lepirudin was approximately 3%.[L41539]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>approved withdrawn</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[BE0000048]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[P00488, P00748, P38435, Q9BQB6, P00734, P08709, P03952, P00451, P13726, P00742, P03951, P00740, P00747, P02671, P05160, P02679, P02452, P02675, P00750, P12259]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>DB00002</td>\n",
       "      <td>Cetuximab</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[DB05209, DB14905, DB06474, DB09381, DB06647, DB11959, DB09052, DB13259, DB12034, DB11857, DB14039, DB12023, DB06305, DB15898, DB14877, DB00814, DB11604, DB12344, DB13886, DB05232, DB14811, DB11884, DB11685, DB11746, DB15118, DB01086, DB14997, DB12815, DB12235, DB06602, DB12053, DB14012, DB09035, DB14891, DB13017, DB01075, DB00108, DB06599, DB06310, DB14864, DB09105, DB12520, DB12396, DB05797,...</td>\n",
       "      <td>ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ANTINEOPLASTIC AGENTS EGFR (Epidermal Growth Factor Receptor) inhibitors</td>\n",
       "      <td>The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein and a type I receptor tyrosine kinase expressed on both normal and malignant cells. It has been investigated as a therapeutic target for anticancer treatment, as it is often upregulated in cancer types, including head and neck, colon, and rectal cancers.[L30448] When activated by its ligand, EGFR undergoes a conformati...</td>\n",
       "      <td>Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF).[A227973] EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible for regulating epithelial tissue development and ho...</td>\n",
       "      <td>After administration of a 400 mg/m&lt;sup&gt;2&lt;/sup&gt; initial dose followed by a 250 mg/m&lt;sup&gt;2&lt;/sup&gt; weekly dose, the mean half-life for cetuximab was approximately 112 hours, with a range of 63 to 230 hours.[L30448]</td>\n",
       "      <td>There is no information available.</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>approved</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[BE0002096, BE0000767, BE0000710, BE0002097, BE0002094, BE0002098, BE0000901, BE0002095]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[P00533]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[P08637, P12318]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>DB00003</td>\n",
       "      <td>Dornase alfa</td>\n",
       "      <td>[BE0004796]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[]</td>\n",
       "      <td>COUGH AND COLD PREPARATIONS Mucolytics EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS RESPIRATORY SYSTEM</td>\n",
       "      <td>Dornase alfa is a biosynthetic form of human DNase I. The enzyme is involved in endonucleolytic cleavage of extracellular DNA to 5´-phosphodinucleotide and 5´-phosphooligonucleotide end products. It has no effect on intracellular DNA. Optimal activity is dependent on the presence of divalent cations such as calcium and magnesium. Extracellular DNA is a viscous anionic polymer and its breakdown...</td>\n",
       "      <td>Dornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme. It is produced in genetically modified Chinese hamster ovary (CHO) cells using recombinant DNA technology. The 260-amino acid sequence of dornase alfa is identical to the endogenous human enzyme. Dornase alfa cleaves extracellular DNA to 5´-phosphodinucleotide and 5´-phosphooligonucleotide end products without a...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>approved</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>DB00004</td>\n",
       "      <td>Denileukin diftitox</td>\n",
       "      <td>[BE0000651, BE0000658, BE0002102]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[DB06770, DB12532, DB00281, DB09107, DB08987, DB00296, DB13259, DB00297, DB13578, DB13683, DB00016, DB01161, DB00961, DB00807, DB11148, DB00907, DB01075, DB00814, DB06774, DB00527, DB00645, DB09345, DB13328, DB09009, DB00721, DB05232, DB08894, DB00750, DB00892, DB00012, DB01002, DB09342, DB09085, DB01086, DB11502, DB03255]</td>\n",
       "      <td>ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS OTHER ANTINEOPLASTIC AGENTS ANTINEOPLASTIC AGENTS Other antineoplastic agents</td>\n",
       "      <td>Denileukin diftitox binds to the high-affinity IL-2 receptor complex. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes. The diphtheria toxin associated with Ontak then selectively kills the IL-2 bearing cells.</td>\n",
       "      <td>A recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133). It is produced in an E. coli expression system.</td>\n",
       "      <td>70-80 min</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>approved investigational</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>DB00005</td>\n",
       "      <td>Etanercept</td>\n",
       "      <td>[BE0009995, BE0000901, BE0000710, BE0001087, BE0002097, BE0002098, BE0000704, BE0002100, BE0002099]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[DB08880, DB00328, DB00682, DB00928, DB15274, DB14649, DB15091, DB00656, DB09052, DB09198, DB06737, DB00916, DB00382, DB15857, DB09570, DB00540, DB00737, DB06712, DB00204, DB01142, DB00092, DB00970, DB00637, DB12130, DB15035, DB08828, DB04951, DB00034, DB00814, DB12978, DB00338, DB09273, DB12945, DB00280, DB05708, DB00642, DB14132, DB00177, DB13068, DB00495, DB03756, DB11921, DB01409, DB00105,...</td>\n",
       "      <td>ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS Tumor necrosis factor alpha (TNF-alpha) inhibitors IMMUNOSUPPRESSANTS</td>\n",
       "      <td>There are two distinct receptors for TNF (TNFRs), a 55 kilodalton protein (p55) and a 75 kilodalton protein (p75). The biological activity of TNF is dependent upon binding to either cell surface receptor (p75 or p55).[A216522] Etanercept is a dimeric soluble form of the p75 TNF receptor that can bind to two TNF molecules, thereby effectively removing them from circulation. Notably, etancerpt i...</td>\n",
       "      <td>Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technology in a Chinese hams...</td>\n",
       "      <td>Etanercept has a mean half-life of elimination of 102 hours in RA patients.[L14862] Population models have shown a mean half-life of 68 hours in healthy adults and 70.7-94.8 hours in pediatric JIA patients.[A215657,A215357]</td>\n",
       "      <td>No significant protein binding has been identified.</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>approved investigational</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>DB00006</td>\n",
       "      <td>Bivalirudin</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[DB13821, DB00328, DB08953, DB00682, DB00928, DB09124, DB13400, DB09381, DB00656, DB09052, DB06679, DB06737, DB03374, DB08814, DB12289, DB06251, DB09217, DB11133, DB00970, DB01066, DB13875, DB13876, DB00034, DB00814, DB00562, DB00036, DB09253, DB01247, DB14006, DB01942, DB00642, DB13510, DB13286, DB00495, DB00232, DB13432, DB13199, DB00105, DB06228, DB13947, DB00305, DB00605, DB00957, DB06715,...</td>\n",
       "      <td>BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS Direct thrombin inhibitors</td>\n",
       "      <td>Inhibits the action of thrombin by binding both to its catalytic site and to its anion-binding exosite. Thrombin is a serine proteinase that plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing fibrin to develop a covalently cross-linked framework which stabilizes the thrombus; thrombin also activ...</td>\n",
       "      <td>Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important to monitor changes in hematocrit, activated partial thromboplastin time, inte...</td>\n",
       "      <td>* Normal renal function: 25 min (in normal conditions)\\n* Creatinine clearance 10-29mL/min: 57min\\n* Dialysis-dependant patients: 3.5h</td>\n",
       "      <td>Other than thrombin and red blood cells, bivalirudin does not bind to plasma proteins.</td>\n",
       "      <td>2180.2853</td>\n",
       "      <td>2178.985813062</td>\n",
       "      <td>approved investigational</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[BE0000048]</td>\n",
       "      <td>[BE0001075]</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[P00488, P00748, P38435, Q9BQB6, P00734, P08709, P03952, P00451, P13726, P00742, P03951, P00740, P00747, P02671, P05160, P02679, P02452, P02675, P00750, P12259]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>DB00007</td>\n",
       "      <td>Leuprolide</td>\n",
       "      <td>[BE0000203]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[DB13821, DB01345, DB00328, DB00682, DB00825, DB01208, DB00928, DB00887, DB00742, DB06196, DB00656, DB09198, DB11891, DB08980, DB06737, DB13259, DB00916, DB00382, DB09570, DB00204, DB06712, DB00540, DB09205, DB01142, DB09217, DB06823, DB00637, DB01066, DB06230, DB06696, DB00814, DB01215, DB11085, DB13446, DB09185, DB00649, DB00562, DB05109, DB00558, DB09209, DB00845, DB14006, DB00280, DB11397,...</td>\n",
       "      <td>ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS Gonadotropin releasing hormone analogues HORMONES AND RELATED AGENTS ENDOCRINE THERAPY</td>\n",
       "      <td>Gonadotropin-releasing hormone (GnRH) is a naturally occurring decapeptide that modulates the hypothalamic-pituitary-gonadal (HPG) axis. GnRH binds to corresponding receptors (GnRHRs) on the anterior pituitary gonadotropes, which in turn release luteinizing hormone (LH) and follicle-stimulating hormone (FSH); these, in turn, affect the downstream synthesis and release of the sex hormones testo...</td>\n",
       "      <td>Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours.[A203222] As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and ...</td>\n",
       "      <td>Leuprolide has a terminal elimination half-life of approximately three hours.[L10310, L13781, L13784, L13787, L13790, L13814, L34415]</td>\n",
       "      <td>Leuprolide displays _in vitro_ binding to human plasma proteins between 43% and 49%.[L10310, L13781, L13784, L13787, L13790, L13814, L34415]</td>\n",
       "      <td>1209.3983</td>\n",
       "      <td>1208.645462232</td>\n",
       "      <td>approved investigational</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>DB00008</td>\n",
       "      <td>Peginterferon alfa-2a</td>\n",
       "      <td>[BE0000661, BE0000385]</td>\n",
       "      <td>[BE0002433]</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[Q8IZI9]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[DB08880, DB00328, DB00682, DB00928, DB15274, DB13400, DB15091, DB09052, DB13259, DB06679, DB00382, DB15857, DB08814, DB12289, DB01142, DB00092, DB00970, DB01078, DB04951, DB00034, DB00814, DB00562, DB12978, DB09273, DB12945, DB00280, DB05708, DB00642, DB14132, DB13068, DB06325, DB05232, DB13510, DB00495, DB00232, DB11921, DB13199, DB00105, DB08844, DB02377, DB01223, DB06228, DB00305, DB01086,...</td>\n",
       "      <td>ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS Interferons IMMUNOSTIMULANTS</td>\n",
       "      <td>Peginterferon alfa-2a is derived from recombinant human interferon's alfa-2a moeity [FDA Label]. It binds to and activates human type 1 interferon receptors causing them to dimerize. This activates the JAK/STAT pathway. Activation of the JAK/STAT pathway increases expression of multiple genes in multiple tissues involved in the innate antiviral response.</td>\n",
       "      <td>Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients [L8...</td>\n",
       "      <td>The mean terminal half-life of peginterferon alfa-2a is 164 in a range of 84-353 hours [FDA Label].</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>approved investigational</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>DB00009</td>\n",
       "      <td>Alteplase</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[DB13821, DB00328, DB08953, DB00682, DB00928, DB09124, DB13400, DB09381, DB06196, DB00656, DB09052, DB06679, DB06737, DB03374, DB00178, DB08814, DB12289, DB06251, DB15944, DB09217, DB11133, DB00970, DB01066, DB13875, DB13876, DB00034, DB00814, DB00562, DB00036, DB09253, DB01247, DB14006, DB01942, DB00177, DB00642, DB13510, DB13286, DB00495, DB00232, DB13432, DB13199, DB00105, DB06228, DB13947,...</td>\n",
       "      <td>OPHTHALMOLOGICALS OTHER OPHTHALMOLOGICALS SENSORY ORGANS Enzymes Other ophthalmologicals ANTITHROMBOTIC AGENTS BLOOD AND BLOOD FORMING ORGANS</td>\n",
       "      <td>Alteplase is a recombinant tissue plasminogen activator (rt-PA) that converts plasminogen to plasmin in a fibrin-dependent process. In the absence of fibrin, alteplase converts a limited amount of plasminogen. However, in the presence of fibrin clots, alteplase binds to fibrin and cleaves the arginine-valine bond at positions 560 and 561 of plasminogen, converting it into its active form, plas...</td>\n",
       "      <td>Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent.[L43125] It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplase and fibrin.[A252330,L43125] Alteplase is a purified glycoprotein o...</td>\n",
       "      <td>Alteplase has an initial half-life of less than 5 minutes in patients with acute myocardial infarction (AMI). The dominant initial plasma half-life of the 3-hour and the accelerated regimens for AMI are similar.[L43125]</td>\n",
       "      <td>Not available.</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>approved investigational</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[BE0000240, BE0000211, BE0002092, BE0000538]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[P00488, P00748, P38435, Q9BQB6, P00734, P08709, P03952, P00451, P13726, P00742, P03951, P00740, P00747, P02671, P05160, P02679, P02452, P02675, P00750, P12259]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>DB00010</td>\n",
       "      <td>Sermorelin</td>\n",
       "      <td>[BE0000625]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[]</td>\n",
       "      <td>OTHER DIAGNOSTIC AGENTS VARIOUS PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES DIAGNOSTIC AGENTS Tests for pituitary function ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES Somatropin and somatropin agonists SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS</td>\n",
       "      <td>Sermorelin binds to the growth hormone releasing hormone receptor and mimics native GRF in its ability to stimulate growth hormone secretion.</td>\n",
       "      <td>Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing hormone (GHRH or GRF) consisting of 44 amino acid residues</td>\n",
       "      <td>11-12 min</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>approved withdrawn</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>DB00011</td>\n",
       "      <td>Interferon alfa-n1</td>\n",
       "      <td>[BE0000661, BE0000385]</td>\n",
       "      <td>[BE0002433]</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[DB08880, DB00328, DB00682, DB00928, DB15274, DB13400, DB15091, DB09052, DB06679, DB00382, DB15857, DB08814, DB12289, DB01142, DB00092, DB00970, DB04951, DB00034, DB00562, DB09273, DB12945, DB00280, DB05708, DB00642, DB14132, DB13068, DB13510, DB00495, DB00232, DB11921, DB13199, DB00105, DB08844, DB02377, DB01223, DB06228, DB00305, DB01086, DB06772, DB16650, DB00277, DB01229, DB00321, DB07615,...</td>\n",
       "      <td>ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS Interferons IMMUNOSTIMULANTS</td>\n",
       "      <td>Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) ...</td>\n",
       "      <td>Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes.</td>\n",
       "      <td>1.2 hours (mammalian reticulocytes, in vitro); &amp;gt;20 hours (yeast, in vivo); &amp;gt;10 hours (Escherichia coli, in vivo).</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>approved investigational</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>DB00012</td>\n",
       "      <td>Darbepoetin alfa</td>\n",
       "      <td>[BE0000654]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[DB01873, DB03946, DB00928, DB12083, DB12036, DB06272, DB12525, DB06647, DB09052, DB11891, DB04786, DB09570, DB13066, DB05786, DB02424, DB12912, DB00970, DB12130, DB12677, DB15035, DB08828, DB04951, DB14877, DB00034, DB12916, DB04858, DB12978, DB00642, DB06159, DB08437, DB06163, DB14811, DB00105, DB00305, DB06772, DB01229, DB06193, DB16479, DB00004, DB11919, DB13912, DB08913, DB13069, DB12422,...</td>\n",
       "      <td>Other antianemic preparations BLOOD AND BLOOD FORMING ORGANS ANTIANEMIC PREPARATIONS OTHER ANTIANEMIC PREPARATIONS</td>\n",
       "      <td>Darbepoetin alfa stimulates erythropoiesis by the same mechanism as endogenous erythropoietin. Erythropoietin interacts with\\nprogenitor stem cells to increase red cell production. Binding of erythropoietin to the erythropoietin receptor leads to receptor dimerization, which facilitates activation of JAK-STAT signaling pathways within the cytosol. Activated STAT (signal transducers and activat...</td>\n",
       "      <td>Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>approved investigational</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>DB00013</td>\n",
       "      <td>Urokinase</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[DB13821, DB00328, DB00682, DB08953, DB00928, DB09124, DB13400, DB09381, DB06196, DB00656, DB09052, DB06679, DB06737, DB03374, DB00178, DB08814, DB12289, DB06251, DB15944, DB09217, DB11133, DB00970, DB01066, DB13875, DB13876, DB00034, DB00814, DB00562, DB00036, DB09253, DB01247, DB14006, DB01942, DB00177, DB00642, DB13510, DB13286, DB00495, DB00232, DB13432, DB13199, DB00105, DB06228, DB13947,...</td>\n",
       "      <td>BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS Enzymes</td>\n",
       "      <td>Urokinase is a serine protease.[A191928] It cleaves plasminogen to form the active fibrinolytic protease, plasmin.[A191928]</td>\n",
       "      <td>Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase.[A191943] Urokinase remains connected between these 2 chains by a sulfhydryl bond.[A191943]\\n\\nUrokinase was granted FDA approval on 16 January 1978.[L12138]</td>\n",
       "      <td>Urokinase has a half life of 12.6±6.2 minutes.[L12138]</td>\n",
       "      <td>Data regarding the protein binding of urokinase in plasma is not readily available.</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>approved investigational withdrawn</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[BE0002112, BE0001656, BE0000942, BE0000240, BE0002113, BE0000717, BE0000211, BE0000969]</td>\n",
       "      <td>[BE0001198]</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[P00488, P00748, P38435, Q9BQB6, P00734, P08709, P03952, P00451, P13726, P00742, P03951, P00740, P00747, P02671, P05160, P02679, P02452, P02675, P00750, P12259]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>DB00014</td>\n",
       "      <td>Goserelin</td>\n",
       "      <td>[BE0000134, BE0000203]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[DB13821, DB01345, DB00328, DB00682, DB00825, DB01208, DB00928, DB00887, DB00742, DB06196, DB00656, DB09198, DB11891, DB08980, DB06737, DB13259, DB00916, DB09570, DB00204, DB06712, DB00540, DB09205, DB01142, DB09217, DB06823, DB00637, DB01066, DB06230, DB06696, DB00814, DB01215, DB11085, DB13446, DB09185, DB00562, DB00558, DB09209, DB00845, DB14006, DB00280, DB11397, DB01200, DB00642, DB08437,...</td>\n",
       "      <td>ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS Gonadotropin releasing hormone analogues HORMONES AND RELATED AGENTS ENDOCRINE THERAPY</td>\n",
       "      <td>Goserelin is a synthetic decapeptide analogue of LHRH. Goserelin acts as a potent inhibitor of pituitary gonadotropin secretion when administered in the biodegradable formulation. The result is sustained suppression of LH and serum testosterone levels.</td>\n",
       "      <td>Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.</td>\n",
       "      <td>4-5 hours</td>\n",
       "      <td>27.3%</td>\n",
       "      <td>1269.4105</td>\n",
       "      <td>1268.641439486</td>\n",
       "      <td>approved</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   drugbank-id                   name                                                                                              targets      enzymes  \\\n",
       "0      DB00001              Lepirudin                                                                                                   []           []   \n",
       "1          NaN                    NaN                                                                                                   []           []   \n",
       "2          NaN                    NaN                                                                                          [BE0000048]           []   \n",
       "3      DB00002              Cetuximab                                                                                                   []           []   \n",
       "4          NaN                    NaN             [BE0002096, BE0000767, BE0000710, BE0002097, BE0002094, BE0002098, BE0000901, BE0002095]           []   \n",
       "5      DB00003           Dornase alfa                                                                                          [BE0004796]           []   \n",
       "6      DB00004    Denileukin diftitox                                                                    [BE0000651, BE0000658, BE0002102]           []   \n",
       "7      DB00005             Etanercept  [BE0009995, BE0000901, BE0000710, BE0001087, BE0002097, BE0002098, BE0000704, BE0002100, BE0002099]           []   \n",
       "8      DB00006            Bivalirudin                                                                                                   []           []   \n",
       "9          NaN                    NaN                                                                                          [BE0000048]  [BE0001075]   \n",
       "10     DB00007             Leuprolide                                                                                          [BE0000203]           []   \n",
       "11     DB00008  Peginterferon alfa-2a                                                                               [BE0000661, BE0000385]  [BE0002433]   \n",
       "12     DB00009              Alteplase                                                                                                   []           []   \n",
       "13         NaN                    NaN                                                         [BE0000240, BE0000211, BE0002092, BE0000538]           []   \n",
       "14     DB00010             Sermorelin                                                                                          [BE0000625]           []   \n",
       "15     DB00011     Interferon alfa-n1                                                                               [BE0000661, BE0000385]  [BE0002433]   \n",
       "16     DB00012       Darbepoetin alfa                                                                                          [BE0000654]           []   \n",
       "17     DB00013              Urokinase                                                                                                   []           []   \n",
       "18         NaN                    NaN             [BE0002112, BE0001656, BE0000942, BE0000240, BE0002113, BE0000717, BE0000211, BE0000969]  [BE0001198]   \n",
       "19     DB00014              Goserelin                                                                               [BE0000134, BE0000203]           []   \n",
       "\n",
       "   transporters carriers  \\\n",
       "0            []      NaN   \n",
       "1            []      NaN   \n",
       "2            []      NaN   \n",
       "3            []      NaN   \n",
       "4            []      NaN   \n",
       "5            []      NaN   \n",
       "6            []      NaN   \n",
       "7            []      NaN   \n",
       "8            []      NaN   \n",
       "9            []      NaN   \n",
       "10           []      NaN   \n",
       "11           []      NaN   \n",
       "12           []      NaN   \n",
       "13           []      NaN   \n",
       "14           []      NaN   \n",
       "15           []      NaN   \n",
       "16           []      NaN   \n",
       "17           []      NaN   \n",
       "18           []      NaN   \n",
       "19           []      NaN   \n",
       "\n",
       "                                                                                                                                                            pathways  \\\n",
       "0                                                                                                                                                                 []   \n",
       "1                                                                                                                                                                 []   \n",
       "2   [P00488, P00748, P38435, Q9BQB6, P00734, P08709, P03952, P00451, P13726, P00742, P03951, P00740, P00747, P02671, P05160, P02679, P02452, P02675, P00750, P12259]   \n",
       "3                                                                                                                                                                 []   \n",
       "4                                                                                                                                                           [P00533]   \n",
       "5                                                                                                                                                                 []   \n",
       "6                                                                                                                                                                 []   \n",
       "7                                                                                                                                                                 []   \n",
       "8                                                                                                                                                                 []   \n",
       "9   [P00488, P00748, P38435, Q9BQB6, P00734, P08709, P03952, P00451, P13726, P00742, P03951, P00740, P00747, P02671, P05160, P02679, P02452, P02675, P00750, P12259]   \n",
       "10                                                                                                                                                                []   \n",
       "11                                                                                                                                                                []   \n",
       "12                                                                                                                                                                []   \n",
       "13  [P00488, P00748, P38435, Q9BQB6, P00734, P08709, P03952, P00451, P13726, P00742, P03951, P00740, P00747, P02671, P05160, P02679, P02452, P02675, P00750, P12259]   \n",
       "14                                                                                                                                                                []   \n",
       "15                                                                                                                                                                []   \n",
       "16                                                                                                                                                                []   \n",
       "17                                                                                                                                                                []   \n",
       "18  [P00488, P00748, P38435, Q9BQB6, P00734, P08709, P03952, P00451, P13726, P00742, P03951, P00740, P00747, P02671, P05160, P02679, P02452, P02675, P00750, P12259]   \n",
       "19                                                                                                                                                                []   \n",
       "\n",
       "   reactions       snp-effects snp-adverse-drug-reactions  \\\n",
       "0         []                []                        NaN   \n",
       "1         []                []                        NaN   \n",
       "2         []                []                        NaN   \n",
       "3         []                []                        NaN   \n",
       "4         []  [P08637, P12318]                        NaN   \n",
       "5         []                []                        NaN   \n",
       "6         []                []                        NaN   \n",
       "7         []                []                        NaN   \n",
       "8         []                []                        NaN   \n",
       "9         []                []                        NaN   \n",
       "10        []                []                        NaN   \n",
       "11        []          [Q8IZI9]                        NaN   \n",
       "12        []                []                        NaN   \n",
       "13        []                []                        NaN   \n",
       "14        []                []                        NaN   \n",
       "15        []                []                        NaN   \n",
       "16        []                []                        NaN   \n",
       "17        []                []                        NaN   \n",
       "18        []                []                        NaN   \n",
       "19        []                []                        NaN   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                  drug-interactions  \\\n",
       "0   [DB13821, DB00328, DB08953, DB00682, DB00928, DB09124, DB13400, DB09381, DB00656, DB09052, DB06679, DB06737, DB03374, DB08814, DB12289, DB06251, DB09217, DB11133, DB00970, DB01066, DB13875, DB13876, DB00034, DB00814, DB00562, DB00036, DB09253, DB01247, DB14006, DB01942, DB00642, DB13510, DB13286, DB00495, DB00232, DB13432, DB13199, DB00105, DB06228, DB13947, DB00305, DB00605, DB00957, DB06715,...   \n",
       "1                                                                                                                                                                                                                                                                                                                                                                                                                []   \n",
       "2                                                                                                                                                                                                                                                                                                                                                                                                                []   \n",
       "3   [DB05209, DB14905, DB06474, DB09381, DB06647, DB11959, DB09052, DB13259, DB12034, DB11857, DB14039, DB12023, DB06305, DB15898, DB14877, DB00814, DB11604, DB12344, DB13886, DB05232, DB14811, DB11884, DB11685, DB11746, DB15118, DB01086, DB14997, DB12815, DB12235, DB06602, DB12053, DB14012, DB09035, DB14891, DB13017, DB01075, DB00108, DB06599, DB06310, DB14864, DB09105, DB12520, DB12396, DB05797,...   \n",
       "4                                                                                                                                                                                                                                                                                                                                                                                                                []   \n",
       "5                                                                                                                                                                                                                                                                                                                                                                                                                []   \n",
       "6                                                                              [DB06770, DB12532, DB00281, DB09107, DB08987, DB00296, DB13259, DB00297, DB13578, DB13683, DB00016, DB01161, DB00961, DB00807, DB11148, DB00907, DB01075, DB00814, DB06774, DB00527, DB00645, DB09345, DB13328, DB09009, DB00721, DB05232, DB08894, DB00750, DB00892, DB00012, DB01002, DB09342, DB09085, DB01086, DB11502, DB03255]   \n",
       "7   [DB08880, DB00328, DB00682, DB00928, DB15274, DB14649, DB15091, DB00656, DB09052, DB09198, DB06737, DB00916, DB00382, DB15857, DB09570, DB00540, DB00737, DB06712, DB00204, DB01142, DB00092, DB00970, DB00637, DB12130, DB15035, DB08828, DB04951, DB00034, DB00814, DB12978, DB00338, DB09273, DB12945, DB00280, DB05708, DB00642, DB14132, DB00177, DB13068, DB00495, DB03756, DB11921, DB01409, DB00105,...   \n",
       "8   [DB13821, DB00328, DB08953, DB00682, DB00928, DB09124, DB13400, DB09381, DB00656, DB09052, DB06679, DB06737, DB03374, DB08814, DB12289, DB06251, DB09217, DB11133, DB00970, DB01066, DB13875, DB13876, DB00034, DB00814, DB00562, DB00036, DB09253, DB01247, DB14006, DB01942, DB00642, DB13510, DB13286, DB00495, DB00232, DB13432, DB13199, DB00105, DB06228, DB13947, DB00305, DB00605, DB00957, DB06715,...   \n",
       "9                                                                                                                                                                                                                                                                                                                                                                                                                []   \n",
       "10  [DB13821, DB01345, DB00328, DB00682, DB00825, DB01208, DB00928, DB00887, DB00742, DB06196, DB00656, DB09198, DB11891, DB08980, DB06737, DB13259, DB00916, DB00382, DB09570, DB00204, DB06712, DB00540, DB09205, DB01142, DB09217, DB06823, DB00637, DB01066, DB06230, DB06696, DB00814, DB01215, DB11085, DB13446, DB09185, DB00649, DB00562, DB05109, DB00558, DB09209, DB00845, DB14006, DB00280, DB11397,...   \n",
       "11  [DB08880, DB00328, DB00682, DB00928, DB15274, DB13400, DB15091, DB09052, DB13259, DB06679, DB00382, DB15857, DB08814, DB12289, DB01142, DB00092, DB00970, DB01078, DB04951, DB00034, DB00814, DB00562, DB12978, DB09273, DB12945, DB00280, DB05708, DB00642, DB14132, DB13068, DB06325, DB05232, DB13510, DB00495, DB00232, DB11921, DB13199, DB00105, DB08844, DB02377, DB01223, DB06228, DB00305, DB01086,...   \n",
       "12  [DB13821, DB00328, DB08953, DB00682, DB00928, DB09124, DB13400, DB09381, DB06196, DB00656, DB09052, DB06679, DB06737, DB03374, DB00178, DB08814, DB12289, DB06251, DB15944, DB09217, DB11133, DB00970, DB01066, DB13875, DB13876, DB00034, DB00814, DB00562, DB00036, DB09253, DB01247, DB14006, DB01942, DB00177, DB00642, DB13510, DB13286, DB00495, DB00232, DB13432, DB13199, DB00105, DB06228, DB13947,...   \n",
       "13                                                                                                                                                                                                                                                                                                                                                                                                               []   \n",
       "14                                                                                                                                                                                                                                                                                                                                                                                                               []   \n",
       "15  [DB08880, DB00328, DB00682, DB00928, DB15274, DB13400, DB15091, DB09052, DB06679, DB00382, DB15857, DB08814, DB12289, DB01142, DB00092, DB00970, DB04951, DB00034, DB00562, DB09273, DB12945, DB00280, DB05708, DB00642, DB14132, DB13068, DB13510, DB00495, DB00232, DB11921, DB13199, DB00105, DB08844, DB02377, DB01223, DB06228, DB00305, DB01086, DB06772, DB16650, DB00277, DB01229, DB00321, DB07615,...   \n",
       "16  [DB01873, DB03946, DB00928, DB12083, DB12036, DB06272, DB12525, DB06647, DB09052, DB11891, DB04786, DB09570, DB13066, DB05786, DB02424, DB12912, DB00970, DB12130, DB12677, DB15035, DB08828, DB04951, DB14877, DB00034, DB12916, DB04858, DB12978, DB00642, DB06159, DB08437, DB06163, DB14811, DB00105, DB00305, DB06772, DB01229, DB06193, DB16479, DB00004, DB11919, DB13912, DB08913, DB13069, DB12422,...   \n",
       "17  [DB13821, DB00328, DB00682, DB08953, DB00928, DB09124, DB13400, DB09381, DB06196, DB00656, DB09052, DB06679, DB06737, DB03374, DB00178, DB08814, DB12289, DB06251, DB15944, DB09217, DB11133, DB00970, DB01066, DB13875, DB13876, DB00034, DB00814, DB00562, DB00036, DB09253, DB01247, DB14006, DB01942, DB00177, DB00642, DB13510, DB13286, DB00495, DB00232, DB13432, DB13199, DB00105, DB06228, DB13947,...   \n",
       "18                                                                                                                                                                                                                                                                                                                                                                                                               []   \n",
       "19  [DB13821, DB01345, DB00328, DB00682, DB00825, DB01208, DB00928, DB00887, DB00742, DB06196, DB00656, DB09198, DB11891, DB08980, DB06737, DB13259, DB00916, DB09570, DB00204, DB06712, DB00540, DB09205, DB01142, DB09217, DB06823, DB00637, DB01066, DB06230, DB06696, DB00814, DB01215, DB11085, DB13446, DB09185, DB00562, DB00558, DB09209, DB00845, DB14006, DB00280, DB11397, DB01200, DB00642, DB08437,...   \n",
       "\n",
       "                                                                                                                                                                                                                                                                             atc-codes  \\\n",
       "0                                                                                                                                                                                                      BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS Direct thrombin inhibitors   \n",
       "1                                                                                                                                                                                                                                                                                  NaN   \n",
       "2                                                                                                                                                                                                                                                                                  NaN   \n",
       "3                                                                                                               ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ANTINEOPLASTIC AGENTS EGFR (Epidermal Growth Factor Receptor) inhibitors   \n",
       "4                                                                                                                                                                                                                                                                                  NaN   \n",
       "5                                                                                                                                                                   COUGH AND COLD PREPARATIONS Mucolytics EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS RESPIRATORY SYSTEM   \n",
       "6                                                                                                                                                             ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS OTHER ANTINEOPLASTIC AGENTS ANTINEOPLASTIC AGENTS Other antineoplastic agents   \n",
       "7                                                                                                                                                                     ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS Tumor necrosis factor alpha (TNF-alpha) inhibitors IMMUNOSUPPRESSANTS   \n",
       "8                                                                                                                                                                                                      BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS Direct thrombin inhibitors   \n",
       "9                                                                                                                                                                                                                                                                                  NaN   \n",
       "10                                                                                                                                                   ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS Gonadotropin releasing hormone analogues HORMONES AND RELATED AGENTS ENDOCRINE THERAPY   \n",
       "11                                                                                                                                                                                                             ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS Interferons IMMUNOSTIMULANTS   \n",
       "12                                                                                                                                       OPHTHALMOLOGICALS OTHER OPHTHALMOLOGICALS SENSORY ORGANS Enzymes Other ophthalmologicals ANTITHROMBOTIC AGENTS BLOOD AND BLOOD FORMING ORGANS   \n",
       "13                                                                                                                                                                                                                                                                                 NaN   \n",
       "14  OTHER DIAGNOSTIC AGENTS VARIOUS PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES DIAGNOSTIC AGENTS Tests for pituitary function ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES Somatropin and somatropin agonists SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS   \n",
       "15                                                                                                                                                                                                             ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS Interferons IMMUNOSTIMULANTS   \n",
       "16                                                                                                                                                                  Other antianemic preparations BLOOD AND BLOOD FORMING ORGANS ANTIANEMIC PREPARATIONS OTHER ANTIANEMIC PREPARATIONS   \n",
       "17                                                                                                                                                                                                                        BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS Enzymes   \n",
       "18                                                                                                                                                                                                                                                                                 NaN   \n",
       "19                                                                                                                                                   ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS Gonadotropin releasing hormone analogues HORMONES AND RELATED AGENTS ENDOCRINE THERAPY   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                mechanism-of-action  \\\n",
       "0   Lepirudin is a direct thrombin inhibitor used as an anticoagulant in patients for whom heparin is contraindicated.[L41539,A3] Thrombin is a serine protease that participates in the blood-clotting cascade, and it is formed by the cleavage of pro-thrombin. Active thrombin cleaves fibrinogen and generates fibrin monomers that polymerize to form fibrin clots.[A246624]\\n\\nLepirudin binds to the cat...   \n",
       "1                                                                                                                                                                                                                                                                                                                                                                                                               NaN   \n",
       "2                                                                                                                                                                                                                                                                                                                                                                                                               NaN   \n",
       "3   The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein and a type I receptor tyrosine kinase expressed on both normal and malignant cells. It has been investigated as a therapeutic target for anticancer treatment, as it is often upregulated in cancer types, including head and neck, colon, and rectal cancers.[L30448] When activated by its ligand, EGFR undergoes a conformati...   \n",
       "4                                                                                                                                                                                                                                                                                                                                                                                                               NaN   \n",
       "5   Dornase alfa is a biosynthetic form of human DNase I. The enzyme is involved in endonucleolytic cleavage of extracellular DNA to 5´-phosphodinucleotide and 5´-phosphooligonucleotide end products. It has no effect on intracellular DNA. Optimal activity is dependent on the presence of divalent cations such as calcium and magnesium. Extracellular DNA is a viscous anionic polymer and its breakdown...   \n",
       "6                                                                                                                                                            Denileukin diftitox binds to the high-affinity IL-2 receptor complex. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes. The diphtheria toxin associated with Ontak then selectively kills the IL-2 bearing cells.   \n",
       "7   There are two distinct receptors for TNF (TNFRs), a 55 kilodalton protein (p55) and a 75 kilodalton protein (p75). The biological activity of TNF is dependent upon binding to either cell surface receptor (p75 or p55).[A216522] Etanercept is a dimeric soluble form of the p75 TNF receptor that can bind to two TNF molecules, thereby effectively removing them from circulation. Notably, etancerpt i...   \n",
       "8   Inhibits the action of thrombin by binding both to its catalytic site and to its anion-binding exosite. Thrombin is a serine proteinase that plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing fibrin to develop a covalently cross-linked framework which stabilizes the thrombus; thrombin also activ...   \n",
       "9                                                                                                                                                                                                                                                                                                                                                                                                               NaN   \n",
       "10  Gonadotropin-releasing hormone (GnRH) is a naturally occurring decapeptide that modulates the hypothalamic-pituitary-gonadal (HPG) axis. GnRH binds to corresponding receptors (GnRHRs) on the anterior pituitary gonadotropes, which in turn release luteinizing hormone (LH) and follicle-stimulating hormone (FSH); these, in turn, affect the downstream synthesis and release of the sex hormones testo...   \n",
       "11                                             Peginterferon alfa-2a is derived from recombinant human interferon's alfa-2a moeity [FDA Label]. It binds to and activates human type 1 interferon receptors causing them to dimerize. This activates the JAK/STAT pathway. Activation of the JAK/STAT pathway increases expression of multiple genes in multiple tissues involved in the innate antiviral response.   \n",
       "12  Alteplase is a recombinant tissue plasminogen activator (rt-PA) that converts plasminogen to plasmin in a fibrin-dependent process. In the absence of fibrin, alteplase converts a limited amount of plasminogen. However, in the presence of fibrin clots, alteplase binds to fibrin and cleaves the arginine-valine bond at positions 560 and 561 of plasminogen, converting it into its active form, plas...   \n",
       "13                                                                                                                                                                                                                                                                                                                                                                                                              NaN   \n",
       "14                                                                                                                                                                                                                                                                    Sermorelin binds to the growth hormone releasing hormone receptor and mimics native GRF in its ability to stimulate growth hormone secretion.   \n",
       "15  Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) ...   \n",
       "16  Darbepoetin alfa stimulates erythropoiesis by the same mechanism as endogenous erythropoietin. Erythropoietin interacts with\\nprogenitor stem cells to increase red cell production. Binding of erythropoietin to the erythropoietin receptor leads to receptor dimerization, which facilitates activation of JAK-STAT signaling pathways within the cytosol. Activated STAT (signal transducers and activat...   \n",
       "17                                                                                                                                                                                                                                                                                      Urokinase is a serine protease.[A191928] It cleaves plasminogen to form the active fibrinolytic protease, plasmin.[A191928]   \n",
       "18                                                                                                                                                                                                                                                                                                                                                                                                              NaN   \n",
       "19                                                                                                                                                     Goserelin is a synthetic decapeptide analogue of LHRH. Goserelin acts as a potent inhibitor of pituitary gonadotropin secretion when administered in the biodegradable formulation. The result is sustained suppression of LH and serum testosterone levels.   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                        description  \\\n",
       "0   Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.[L41539,L41569] Natural hirudin is an endogenous anticoagulant found in _Hirudo medicinalis_ leeches.[L41539] Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence of sulfate on the tyrosine residue at position 63 and the substitutio...   \n",
       "1                                                                                                                                                                                                                                                                                                                                                                                                               NaN   \n",
       "2                                                                                                                                                                                                                                                                                                                                                                                                               NaN   \n",
       "3   Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF).[A227973] EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible for regulating epithelial tissue development and ho...   \n",
       "4                                                                                                                                                                                                                                                                                                                                                                                                               NaN   \n",
       "5   Dornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme. It is produced in genetically modified Chinese hamster ovary (CHO) cells using recombinant DNA technology. The 260-amino acid sequence of dornase alfa is identical to the endogenous human enzyme. Dornase alfa cleaves extracellular DNA to 5´-phosphodinucleotide and 5´-phosphooligonucleotide end products without a...   \n",
       "6                                                                                                                                                    A recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133). It is produced in an E. coli expression system.   \n",
       "7   Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technology in a Chinese hams...   \n",
       "8   Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important to monitor changes in hematocrit, activated partial thromboplastin time, inte...   \n",
       "9                                                                                                                                                                                                                                                                                                                                                                                                               NaN   \n",
       "10  Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours.[A203222] As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and ...   \n",
       "11  Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients [L8...   \n",
       "12  Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent.[L43125] It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplase and fibrin.[A252330,L43125] Alteplase is a purified glycoprotein o...   \n",
       "13                                                                                                                                                                                                                                                                                                                                                                                                              NaN   \n",
       "14                                                                                                                                       Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing hormone (GHRH or GRF) consisting of 44 amino acid residues   \n",
       "15                                                                                                                          Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes.   \n",
       "16                                                                                                                                                                                                                 Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.   \n",
       "17                                                                                                      Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase.[A191943] Urokinase remains connected between these 2 chains by a sulfhydryl bond.[A191943]\\n\\nUrokinase was granted FDA approval on 16 January 1978.[L12138]   \n",
       "18                                                                                                                                                                                                                                                                                                                                                                                                              NaN   \n",
       "19                              Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                          half-life  \\\n",
       "0   Lepirudin has an initial half-life of approximately 10 minutes, and in young healthy volunteers, it has a terminal half-time of 1.3 hours.[L41539] Lepirudin has a first-order elimination kinetic; plasma concentration increases proportionally as the lepirudin intravenous dose is increased. Elimination half-life values of up to 2 days were detected in patients with marked renal insufficiency (cr...   \n",
       "1                                                                                                                                                                                                                                                                                                                                                                                                               NaN   \n",
       "2                                                                                                                                                                                                                                                                                                                                                                                                               NaN   \n",
       "3                                                                                                                                                                                                After administration of a 400 mg/m<sup>2</sup> initial dose followed by a 250 mg/m<sup>2</sup> weekly dose, the mean half-life for cetuximab was approximately 112 hours, with a range of 63 to 230 hours.[L30448]   \n",
       "4                                                                                                                                                                                                                                                                                                                                                                                                               NaN   \n",
       "5                                                                                                                                                                                                                                                                                                                                                                                                               NaN   \n",
       "6                                                                                                                                                                                                                                                                                                                                                                                                         70-80 min   \n",
       "7                                                                                                                                                                                   Etanercept has a mean half-life of elimination of 102 hours in RA patients.[L14862] Population models have shown a mean half-life of 68 hours in healthy adults and 70.7-94.8 hours in pediatric JIA patients.[A215657,A215357]   \n",
       "8                                                                                                                                                                                                                                                                            * Normal renal function: 25 min (in normal conditions)\\n* Creatinine clearance 10-29mL/min: 57min\\n* Dialysis-dependant patients: 3.5h   \n",
       "9                                                                                                                                                                                                                                                                                                                                                                                                               NaN   \n",
       "10                                                                                                                                                                                                                                                                            Leuprolide has a terminal elimination half-life of approximately three hours.[L10310, L13781, L13784, L13787, L13790, L13814, L34415]   \n",
       "11                                                                                                                                                                                                                                                                                                              The mean terminal half-life of peginterferon alfa-2a is 164 in a range of 84-353 hours [FDA Label].   \n",
       "12                                                                                                                                                                                      Alteplase has an initial half-life of less than 5 minutes in patients with acute myocardial infarction (AMI). The dominant initial plasma half-life of the 3-hour and the accelerated regimens for AMI are similar.[L43125]   \n",
       "13                                                                                                                                                                                                                                                                                                                                                                                                              NaN   \n",
       "14                                                                                                                                                                                                                                                                                                                                                                                                        11-12 min   \n",
       "15                                                                                                                                                                                                                                                                                          1.2 hours (mammalian reticulocytes, in vitro); &gt;20 hours (yeast, in vivo); &gt;10 hours (Escherichia coli, in vivo).   \n",
       "16                                                                                                                                                                                                                                                                                                                                                                                                              NaN   \n",
       "17                                                                                                                                                                                                                                                                                                                                                           Urokinase has a half life of 12.6±6.2 minutes.[L12138]   \n",
       "18                                                                                                                                                                                                                                                                                                                                                                                                              NaN   \n",
       "19                                                                                                                                                                                                                                                                                                                                                                                                        4-5 hours   \n",
       "\n",
       "                                                                                                                                 protein-binding average-mass  \\\n",
       "0                                                                In human plasma, the protein binding of lepirudin was approximately 3%.[L41539]          NaN   \n",
       "1                                                                                                                                            NaN          NaN   \n",
       "2                                                                                                                                            NaN          NaN   \n",
       "3                                                                                                             There is no information available.          NaN   \n",
       "4                                                                                                                                            NaN          NaN   \n",
       "5                                                                                                                                            NaN          NaN   \n",
       "6                                                                                                                                            NaN          NaN   \n",
       "7                                                                                            No significant protein binding has been identified.          NaN   \n",
       "8                                                         Other than thrombin and red blood cells, bivalirudin does not bind to plasma proteins.    2180.2853   \n",
       "9                                                                                                                                            NaN          NaN   \n",
       "10  Leuprolide displays _in vitro_ binding to human plasma proteins between 43% and 49%.[L10310, L13781, L13784, L13787, L13790, L13814, L34415]    1209.3983   \n",
       "11                                                                                                                                           NaN          NaN   \n",
       "12                                                                                                                                Not available.          NaN   \n",
       "13                                                                                                                                           NaN          NaN   \n",
       "14                                                                                                                                           NaN          NaN   \n",
       "15                                                                                                                                           NaN          NaN   \n",
       "16                                                                                                                                           NaN          NaN   \n",
       "17                                                           Data regarding the protein binding of urokinase in plasma is not readily available.          NaN   \n",
       "18                                                                                                                                           NaN          NaN   \n",
       "19                                                                                                                                         27.3%    1269.4105   \n",
       "\n",
       "   monoisotopic-mass                              groups  \n",
       "0                NaN                  approved withdrawn  \n",
       "1                NaN                                 NaN  \n",
       "2                NaN                                 NaN  \n",
       "3                NaN                            approved  \n",
       "4                NaN                                 NaN  \n",
       "5                NaN                            approved  \n",
       "6                NaN            approved investigational  \n",
       "7                NaN            approved investigational  \n",
       "8     2178.985813062            approved investigational  \n",
       "9                NaN                                 NaN  \n",
       "10    1208.645462232            approved investigational  \n",
       "11               NaN            approved investigational  \n",
       "12               NaN            approved investigational  \n",
       "13               NaN                                 NaN  \n",
       "14               NaN                  approved withdrawn  \n",
       "15               NaN            approved investigational  \n",
       "16               NaN            approved investigational  \n",
       "17               NaN  approved investigational withdrawn  \n",
       "18               NaN                                 NaN  \n",
       "19    1268.641439486                            approved  "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Cell 4: parsing helper\n",
    "if 'df' in globals():\n",
    "    def parse_id_list(cell):\n",
    "        if pd.isna(cell):\n",
    "            return []\n",
    "        s = str(cell).strip()\n",
    "        if s == \"[]\":\n",
    "            return []\n",
    "        tokens = re.split(r'[\\s;,\\|]+', s)\n",
    "        tokens = [t.strip() for t in tokens if t.strip()!='' and t.strip()!=\"nan\"]\n",
    "        return tokens\n",
    "\n",
    "    cols_interest = [\"drugbank-id\",\"name\",\"targets\",\"enzymes\",\"transporters\",\"carriers\",\"pathways\",\n",
    "                     \"reactions\",\"snp-effects\",\"snp-adverse-drug-reactions\",\"drug-interactions\",\n",
    "                     \"atc-codes\",\"mechanism-of-action\",\"description\",\"half-life\",\"protein-binding\",\n",
    "                     \"average-mass\",\"monoisotopic-mass\",\"groups\"]\n",
    "    cols_present = [c for c in cols_interest if c in df.columns]\n",
    "    display(Markdown(f\"Columns present from interest list: {cols_present}\"))\n",
    "\n",
    "    sample = df[cols_present].head(20).copy()\n",
    "    for col in [\"targets\",\"enzymes\",\"transporters\",\"pathways\",\"reactions\",\"snp-effects\",\"drug-interactions\"]:\n",
    "        if col in sample:\n",
    "            sample[col] = sample[col].apply(parse_id_list)\n",
    "    display(Markdown(\"Sample parsed rows\"))\n",
    "    display(sample.head(20))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "0d5c6a0f",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/markdown": [
       "Using canonical id column: **drugbank-id**"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/markdown": [
       "Mappings built. Quick counts:"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>drugs_total</th>\n",
       "      <th>drugs_with_targets</th>\n",
       "      <th>drugs_with_enzymes</th>\n",
       "      <th>drugs_with_transporters</th>\n",
       "      <th>drugs_with_interactions</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>15235</td>\n",
       "      <td>7296</td>\n",
       "      <td>1541</td>\n",
       "      <td>804</td>\n",
       "      <td>4478</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   drugs_total  drugs_with_targets  drugs_with_enzymes  drugs_with_transporters  drugs_with_interactions\n",
       "0        15235                7296                1541                      804                     4478"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Cell 5: build drug -> entity mappings\n",
    "if 'df' in globals():\n",
    "    drug_id_col = \"drugbank-id\" if \"drugbank-id\" in df.columns else \"name\"\n",
    "    display(Markdown(f\"Using canonical id column: **{drug_id_col}**\"))\n",
    "\n",
    "    drug_to_targets = {}\n",
    "    drug_to_enzymes = {}\n",
    "    drug_to_transporters = {}\n",
    "    drug_to_pathways = {}\n",
    "    drug_to_reactions = {}\n",
    "    drug_to_snps = {}\n",
    "    drug_to_interactions = {}\n",
    "\n",
    "    for idx, row in df.iterrows():\n",
    "        did = row.get(drug_id_col)\n",
    "        if pd.isna(did): \n",
    "            continue\n",
    "        did = str(did).strip()\n",
    "        def get_list(col):\n",
    "            return parse_id_list(row.get(col)) if col in df.columns else []\n",
    "        drug_to_targets.setdefault(did, []).extend(get_list(\"targets\"))\n",
    "        drug_to_enzymes.setdefault(did, []).extend(get_list(\"enzymes\"))\n",
    "        drug_to_transporters.setdefault(did, []).extend(get_list(\"transporters\"))\n",
    "        drug_to_pathways.setdefault(did, []).extend(get_list(\"pathways\"))\n",
    "        drug_to_reactions.setdefault(did, []).extend(get_list(\"reactions\"))\n",
    "        drug_to_snps.setdefault(did, []).extend(get_list(\"snp-effects\"))\n",
    "        # naive extraction for drug-interactions (DB or BE tokens)\n",
    "        if \"drug-interactions\" in df.columns:\n",
    "            cell = row.get(\"drug-interactions\")\n",
    "            if not pd.isna(cell):\n",
    "                raw_tokens = re.split(r'[\\s;,\\|]+', str(cell))\n",
    "                parsed = [t for t in raw_tokens if re.match(r'^(BE|DB)\\w+', t)]\n",
    "            else:\n",
    "                parsed = []\n",
    "            drug_to_interactions.setdefault(did, []).extend(parsed)\n",
    "\n",
    "    def uniq(d): return {k: list(dict.fromkeys(v)) for k,v in d.items()}\n",
    "    drug_to_targets = uniq(drug_to_targets)\n",
    "    drug_to_enzymes = uniq(drug_to_enzymes)\n",
    "    drug_to_transporters = uniq(drug_to_transporters)\n",
    "    drug_to_pathways = uniq(drug_to_pathways)\n",
    "    drug_to_reactions = uniq(drug_to_reactions)\n",
    "    drug_to_snps = uniq(drug_to_snps)\n",
    "    drug_to_interactions = uniq(drug_to_interactions)\n",
    "\n",
    "    display(Markdown(\"Mappings built. Quick counts:\"))\n",
    "    display(pd.DataFrame({\n",
    "        \"drugs_total\": [len(set(df[drug_id_col].dropna()))],\n",
    "        \"drugs_with_targets\": [sum(1 for k,v in drug_to_targets.items() if v)],\n",
    "        \"drugs_with_enzymes\": [sum(1 for k,v in drug_to_enzymes.items() if v)],\n",
    "        \"drugs_with_transporters\": [sum(1 for k,v in drug_to_transporters.items() if v)],\n",
    "        \"drugs_with_interactions\": [sum(1 for k,v in drug_to_interactions.items() if v)]\n",
    "    }))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "e121ff53",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/markdown": [
       "Top proteins by frequency"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>protein_id</th>\n",
       "      <th>count</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>BE0002638</td>\n",
       "      <td>835</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>BE0001032</td>\n",
       "      <td>463</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>BE0002363</td>\n",
       "      <td>301</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>BE0002433</td>\n",
       "      <td>293</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>BE0002793</td>\n",
       "      <td>291</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>BE0003536</td>\n",
       "      <td>249</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>BE0002887</td>\n",
       "      <td>226</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>BE0002362</td>\n",
       "      <td>212</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>BE0001067</td>\n",
       "      <td>193</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>BE0003549</td>\n",
       "      <td>160</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>BE0001004</td>\n",
       "      <td>150</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>BE0001072</td>\n",
       "      <td>136</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>BE0003533</td>\n",
       "      <td>113</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>BE0000048</td>\n",
       "      <td>112</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>BE0003659</td>\n",
       "      <td>112</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>BE0003645</td>\n",
       "      <td>111</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>BE0000123</td>\n",
       "      <td>108</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>BE0000756</td>\n",
       "      <td>100</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>BE0001739</td>\n",
       "      <td>99</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>BE0000451</td>\n",
       "      <td>97</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   protein_id  count\n",
       "0   BE0002638    835\n",
       "1   BE0001032    463\n",
       "2   BE0002363    301\n",
       "3   BE0002433    293\n",
       "4   BE0002793    291\n",
       "5   BE0003536    249\n",
       "6   BE0002887    226\n",
       "7   BE0002362    212\n",
       "8   BE0001067    193\n",
       "9   BE0003549    160\n",
       "10  BE0001004    150\n",
       "11  BE0001072    136\n",
       "12  BE0003533    113\n",
       "13  BE0000048    112\n",
       "14  BE0003659    112\n",
       "15  BE0003645    111\n",
       "16  BE0000123    108\n",
       "17  BE0000756    100\n",
       "18  BE0001739     99\n",
       "19  BE0000451     97"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Cell 6: top protein frequencies\n",
    "if 'df' in globals():\n",
    "    counter = Counter()\n",
    "    for v in drug_to_targets.values(): counter.update(v)\n",
    "    for v in drug_to_enzymes.values(): counter.update(v)\n",
    "    for v in drug_to_transporters.values(): counter.update(v)\n",
    "    top = pd.DataFrame(counter.most_common(40), columns=[\"protein_id\",\"count\"])\n",
    "    display(Markdown(\"Top proteins by frequency\"))\n",
    "    display(top.head(20))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "da9f59f8",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "c:\\Users\\anujm\\anaconda3\\envs\\DDI\\lib\\site-packages\\tqdm\\auto.py:21: TqdmWarning: IProgress not found. Please update jupyter and ipywidgets. See https://ipywidgets.readthedocs.io/en/stable/user_install.html\n",
      "  from .autonotebook import tqdm as notebook_tqdm\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "## Building Heterogeneous Graph with PyTorch Geometric"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/markdown": [
       "Total drug nodes: **15235**"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/markdown": [
       "Total protein nodes: **5528**"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/markdown": [
       "Target edges: **16040**"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/markdown": [
       "Enzyme edges: **10386**"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/markdown": [
       "Transporter edges: **2354**"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/markdown": [
       "DDI edges: **2866522**"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "HeteroData(\n",
      "  drug={ num_nodes=15235 },\n",
      "  protein={ num_nodes=5528 },\n",
      "  (drug, targets, protein)={ edge_index=[2, 16040] },\n",
      "  (drug, enzymes, protein)={ edge_index=[2, 10386] },\n",
      "  (drug, transporters, protein)={ edge_index=[2, 2354] },\n",
      "  (drug, interacts, drug)={ edge_index=[2, 2866522] }\n",
      ")\n"
     ]
    }
   ],
   "source": [
    "# Cell 7 — Build Heterogeneous Graph Using PyTorch Geometric \n",
    "from torch_geometric.data import HeteroData\n",
    "import torch\n",
    "\n",
    "display(Markdown(\"## Building Heterogeneous Graph with PyTorch Geometric\"))\n",
    "\n",
    "# 1. Build node index dictionaries\n",
    "drug_ids = sorted(list(set(df[drug_id_col].dropna())))\n",
    "protein_ids = set()\n",
    "\n",
    "# Collect all protein-like IDs (targets, enzymes, transporters)\n",
    "for did in drug_ids:\n",
    "    protein_ids.update(drug_to_targets.get(did, []))\n",
    "    protein_ids.update(drug_to_enzymes.get(did, []))\n",
    "    protein_ids.update(drug_to_transporters.get(did, []))\n",
    "\n",
    "protein_ids = sorted(list(protein_ids))\n",
    "\n",
    "# Build index maps\n",
    "drug_index = {d: i for i, d in enumerate(drug_ids)}\n",
    "protein_index = {p: i for i, p in enumerate(protein_ids)}\n",
    "\n",
    "display(Markdown(f\"Total drug nodes: **{len(drug_index)}**\"))\n",
    "display(Markdown(f\"Total protein nodes: **{len(protein_index)}**\"))\n",
    "\n",
    "# 2. Create PyG HeteroData object\n",
    "data = HeteroData()\n",
    "\n",
    "# add node counts\n",
    "data['drug'].num_nodes = len(drug_index)\n",
    "data['protein'].num_nodes = len(protein_index)\n",
    "\n",
    "\n",
    "# 3. Add drug→protein edges for each relation type\n",
    "def make_edge_tensor(edge_list):\n",
    "    if len(edge_list) == 0:\n",
    "        return torch.empty((2,0), dtype=torch.long)\n",
    "    edge_index = torch.tensor(edge_list, dtype=torch.long).t().contiguous()\n",
    "    return edge_index\n",
    "\n",
    "# build relation edges separately\n",
    "drug_target_edges = []\n",
    "drug_enzyme_edges = []\n",
    "drug_transporter_edges = []\n",
    "\n",
    "for did in drug_ids:\n",
    "    u = drug_index[did]\n",
    "    # targets\n",
    "    for prot in drug_to_targets.get(did, []):\n",
    "        if prot in protein_index:\n",
    "            drug_target_edges.append([u, protein_index[prot]])\n",
    "    # enzymes\n",
    "    for prot in drug_to_enzymes.get(did, []):\n",
    "        if prot in protein_index:\n",
    "            drug_enzyme_edges.append([u, protein_index[prot]])\n",
    "    # transporters\n",
    "    for prot in drug_to_transporters.get(did, []):\n",
    "        if prot in protein_index:\n",
    "            drug_transporter_edges.append([u, protein_index[prot]])\n",
    "\n",
    "data['drug', 'targets', 'protein'].edge_index = make_edge_tensor(drug_target_edges)\n",
    "data['drug', 'enzymes', 'protein'].edge_index = make_edge_tensor(drug_enzyme_edges)\n",
    "data['drug', 'transporters', 'protein'].edge_index = make_edge_tensor(drug_transporter_edges)\n",
    "\n",
    "display(Markdown(f\"Target edges: **{len(drug_target_edges)}**\"))\n",
    "display(Markdown(f\"Enzyme edges: **{len(drug_enzyme_edges)}**\"))\n",
    "display(Markdown(f\"Transporter edges: **{len(drug_transporter_edges)}**\"))\n",
    "\n",
    "\n",
    "# 4. Add drug↔drug interactions (DDI links)\n",
    "ddi_edges = []\n",
    "for a, lst in drug_to_interactions.items():\n",
    "    if a in drug_index:\n",
    "        for b in lst:\n",
    "            if b in drug_index:\n",
    "                # undirected → save one direction\n",
    "                u, v = drug_index[a], drug_index[b]\n",
    "                if u != v:\n",
    "                    ddi_edges.append([u, v])\n",
    "\n",
    "data['drug', 'interacts', 'drug'].edge_index = make_edge_tensor(ddi_edges)\n",
    "display(Markdown(f\"DDI edges: **{len(ddi_edges)}**\"))\n",
    "\n",
    "print(data)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "3b06a675",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/markdown": [
       "## Basic Graph Statistics (PyG)"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/markdown": [
       "### Drug Node Degree Stats"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>min_degree</th>\n",
       "      <th>max_degree</th>\n",
       "      <th>mean_degree</th>\n",
       "      <th>median_degree</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0</td>\n",
       "      <td>2535</td>\n",
       "      <td>190.042801</td>\n",
       "      <td>1.0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   min_degree  max_degree  mean_degree  median_degree\n",
       "0           0        2535   190.042801            1.0"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 600x400 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Cell 8 — Graph Statistics Using PyG \n",
    "\n",
    "from torch_geometric.utils import degree\n",
    "\n",
    "display(Markdown(\"## Basic Graph Statistics (PyG)\"))\n",
    "\n",
    "# Degree of drug nodes (considering all drug→protein and drug→drug edges)\n",
    "deg_drug = torch.zeros(data['drug'].num_nodes, dtype=torch.long)\n",
    "\n",
    "# accumulate degree from each relation\n",
    "for rel in [('drug','targets','protein'),\n",
    "            ('drug','enzymes','protein'),\n",
    "            ('drug','transporters','protein'),\n",
    "            ('drug','interacts','drug')]:\n",
    "\n",
    "    edge_index = data[rel].edge_index\n",
    "    for src in edge_index[0]:\n",
    "        deg_drug[src] += 1\n",
    "\n",
    "display(Markdown(\"### Drug Node Degree Stats\"))\n",
    "display(pd.DataFrame({\n",
    "    \"min_degree\": [int(deg_drug.min())],\n",
    "    \"max_degree\": [int(deg_drug.max())],\n",
    "    \"mean_degree\": [float(deg_drug.float().mean())],\n",
    "    \"median_degree\": [float(deg_drug.float().median())]\n",
    "}))\n",
    "\n",
    "plt.figure(figsize=(6,4))\n",
    "sns.histplot(deg_drug.numpy(), bins=50, log_scale=(False, True))\n",
    "plt.title(\"Drug Node Degree Distribution (log y)\")\n",
    "plt.xlabel(\"Degree\")\n",
    "plt.show()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "25f418bf",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/markdown": [
       "## Pairwise EDA — Shared Proteins vs Known DDI"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>drug_a</th>\n",
       "      <th>drug_b</th>\n",
       "      <th>is_known</th>\n",
       "      <th>shared_targets</th>\n",
       "      <th>shared_enzymes</th>\n",
       "      <th>shared_transporters</th>\n",
       "      <th>shared_pathways</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>DB03714</td>\n",
       "      <td>DB05016</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>DB02307</td>\n",
       "      <td>DB03834</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>DB01701</td>\n",
       "      <td>DB03912</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>DB02590</td>\n",
       "      <td>DB03779</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>DB01140</td>\n",
       "      <td>DB02410</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "    drug_a   drug_b  is_known  shared_targets  shared_enzymes  shared_transporters  shared_pathways\n",
       "0  DB03714  DB05016         0               0               0                    0                0\n",
       "1  DB02307  DB03834         0               0               0                    0                0\n",
       "2  DB01701  DB03912         0               0               0                    0                0\n",
       "3  DB02590  DB03779         0               0               0                    0                0\n",
       "4  DB01140  DB02410         0               0               0                    0                0"
      ]
     },
     "execution_count": 17,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Cell 9 — Pairwise protein-overlap EDA\n",
    "\n",
    "display(Markdown(\"## Pairwise EDA — Shared Proteins vs Known DDI\"))\n",
    "\n",
    "usable_drugs = [\n",
    "    d for d in drug_ids \n",
    "    if (drug_to_targets.get(d) or drug_to_enzymes.get(d) or drug_to_transporters.get(d))\n",
    "]\n",
    "\n",
    "def shared_counts(d1, d2):\n",
    "    return {\n",
    "        \"shared_targets\": len(set(drug_to_targets.get(d1, [])) & set(drug_to_targets.get(d2, []))),\n",
    "        \"shared_enzymes\": len(set(drug_to_enzymes.get(d1, [])) & set(drug_to_enzymes.get(d2, []))),\n",
    "        \"shared_transporters\": len(set(drug_to_transporters.get(d1, [])) & set(drug_to_transporters.get(d2, []))),\n",
    "        \"shared_pathways\": len(set(drug_to_pathways.get(d1, [])) & set(drug_to_pathways.get(d2, []))),\n",
    "    }\n",
    "\n",
    "known_pairs = {\n",
    "    tuple(sorted([a,b]))\n",
    "    for a,lst in drug_to_interactions.items()\n",
    "    for b in lst\n",
    "    if a in drug_index and b in drug_index\n",
    "}\n",
    "\n",
    "N_SAMPLE = 20000\n",
    "sampled_pairs = set()\n",
    "import random\n",
    "random.seed(42)\n",
    "\n",
    "drug_sample = usable_drugs[:4000] if len(usable_drugs)>4000 else usable_drugs\n",
    "while len(sampled_pairs) < N_SAMPLE:\n",
    "    a,b = random.sample(drug_sample, 2)\n",
    "    sampled_pairs.add(tuple(sorted([a,b])))\n",
    "\n",
    "rows = []\n",
    "for a,b in sampled_pairs:\n",
    "    feats = shared_counts(a,b)\n",
    "    rows.append({\n",
    "        \"drug_a\":a, \"drug_b\":b,\n",
    "        \"is_known\":1 if (a,b) in known_pairs else 0,\n",
    "        **feats\n",
    "    })\n",
    "\n",
    "pairdf = pd.DataFrame(rows)\n",
    "pairdf.head()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "48210358",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1200x400 with 2 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>shared_targets</th>\n",
       "      <th>shared_enzymes</th>\n",
       "      <th>shared_transporters</th>\n",
       "      <th>shared_pathways</th>\n",
       "      <th>is_known</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>shared_targets</th>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.030781</td>\n",
       "      <td>0.015697</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.199026</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>shared_enzymes</th>\n",
       "      <td>0.030781</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.072386</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.128554</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>shared_transporters</th>\n",
       "      <td>0.015697</td>\n",
       "      <td>0.072386</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.150244</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>shared_pathways</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>is_known</th>\n",
       "      <td>0.199026</td>\n",
       "      <td>0.128554</td>\n",
       "      <td>0.150244</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.000000</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                     shared_targets  shared_enzymes  shared_transporters  shared_pathways  is_known\n",
       "shared_targets             1.000000        0.030781             0.015697              NaN  0.199026\n",
       "shared_enzymes             0.030781        1.000000             0.072386              NaN  0.128554\n",
       "shared_transporters        0.015697        0.072386             1.000000              NaN  0.150244\n",
       "shared_pathways                 NaN             NaN                  NaN              NaN       NaN\n",
       "is_known                   0.199026        0.128554             0.150244              NaN  1.000000"
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Cell 10 — Probability Plots & Correlations\n",
    "\n",
    "def prob_by(x):\n",
    "    g = pairdf.groupby(x)['is_known'].agg(['mean','count']).reset_index()\n",
    "    return g[g['count']>10]\n",
    "\n",
    "p1 = prob_by(\"shared_targets\")\n",
    "p2 = prob_by(\"shared_enzymes\")\n",
    "\n",
    "plt.figure(figsize=(12,4))\n",
    "plt.subplot(1,2,1)\n",
    "sns.lineplot(data=p1, x='shared_targets', y='mean', marker='o')\n",
    "plt.title(\"P(DDI) vs Shared Targets\")\n",
    "\n",
    "plt.subplot(1,2,2)\n",
    "sns.lineplot(data=p2, x='shared_enzymes', y='mean', marker='o')\n",
    "plt.title(\"P(DDI) vs Shared Enzymes\")\n",
    "\n",
    "plt.show()\n",
    "\n",
    "pairdf[[\"shared_targets\",\"shared_enzymes\",\"shared_transporters\",\"shared_pathways\",\"is_known\"]].corr()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "a41d7283",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/markdown": [
       "If you want to persist node/edge lists for modeling, use the snippet below (uncomment to run)"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "# Example saving snippet (uncomment to run)\n",
      "# drug_index = {d:i for i,d in enumerate(sorted([n for n,a in G.nodes(data=True) if a.get('ntype')=='drug']))}\n",
      "# prot_index = {p:i for i,p in enumerate(sorted([n for n,a in G.nodes(data=True) if a.get('ntype')!='drug']))}\n",
      "# drug_target_edges = [(drug_index[u], prot_index[v]) for u,v,a in G.edges(data=True) if a.get('etype')=='target']\n",
      "# ddi_edges = [(drug_index[a], drug_index[b]) for a,b in known_pairs if a in drug_index and b in drug_index]\n",
      "# pd.DataFrame(drug_target_edges, columns=['drug_idx','prot_idx']).to_csv('drug_target_edges.csv', index=False)\n",
      "# pd.DataFrame(ddi_edges, columns=['drug_a','drug_b']).to_csv('ddi_edges.csv', index=False)\n",
      "\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "PyG HeteroData example (requires torch + torch_geometric):"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "# from torch_geometric.data import HeteroData\n",
      "# data = HeteroData()\n",
      "# data['drug'].num_nodes = len(drug_index)\n",
      "# data['protein'].num_nodes = len(prot_index)\n",
      "# data['drug','targets','protein'].edge_index = torch.tensor(list(zip(*drug_target_edges)), dtype=torch.long)\n",
      "# data['drug','interacts','drug'].edge_index = torch.tensor(list(zip(*ddi_edges)), dtype=torch.long)\n",
      "# torch.save(data, 'drugbank_heterodata.pt')\n",
      "\n"
     ]
    }
   ],
   "source": [
    "# Cell 11: Save artifacts and show PyG snippet\n",
    "if 'df' in globals():\n",
    "    display(Markdown(\"If you want to persist node/edge lists for modeling, use the snippet below (uncomment to run)\"))\n",
    "    print(r\"\"\"\n",
    "# Example saving snippet (uncomment to run)\n",
    "# drug_index = {d:i for i,d in enumerate(sorted([n for n,a in G.nodes(data=True) if a.get('ntype')=='drug']))}\n",
    "# prot_index = {p:i for i,p in enumerate(sorted([n for n,a in G.nodes(data=True) if a.get('ntype')!='drug']))}\n",
    "# drug_target_edges = [(drug_index[u], prot_index[v]) for u,v,a in G.edges(data=True) if a.get('etype')=='target']\n",
    "# ddi_edges = [(drug_index[a], drug_index[b]) for a,b in known_pairs if a in drug_index and b in drug_index]\n",
    "# pd.DataFrame(drug_target_edges, columns=['drug_idx','prot_idx']).to_csv('drug_target_edges.csv', index=False)\n",
    "# pd.DataFrame(ddi_edges, columns=['drug_a','drug_b']).to_csv('ddi_edges.csv', index=False)\n",
    "\"\"\")\n",
    "    display(Markdown(\"PyG HeteroData example (requires torch + torch_geometric):\"))\n",
    "    print(r\"\"\"\n",
    "# from torch_geometric.data import HeteroData\n",
    "# data = HeteroData()\n",
    "# data['drug'].num_nodes = len(drug_index)\n",
    "# data['protein'].num_nodes = len(prot_index)\n",
    "# data['drug','targets','protein'].edge_index = torch.tensor(list(zip(*drug_target_edges)), dtype=torch.long)\n",
    "# data['drug','interacts','drug'].edge_index = torch.tensor(list(zip(*ddi_edges)), dtype=torch.long)\n",
    "# torch.save(data, 'drugbank_heterodata.pt')\n",
    "\"\"\")\n"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "DDI",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.19"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
